Document:

EX-10.10

 Exhibit 10.10 

CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[***]”. AN
UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 
 MASTER DEVELOPMENT AND MANUFACTURING AGREEMENT 

This Master Development and Manufacturing Agreement (including all appendices hereto, this “Agreement”) is entered into as of
February 13, 2018 (the “Effective Date”) by and between Magenta Therapeutics, Inc., a Delaware corporation having offices at 50 Hampshire Street, 8th Floor, Cambridge, MA
02139 (“Magenta”), and Bachem Americas, Inc., a California corporation, having offices at 3132 Kashiwa Street, Torrance, CA 90505 (“Bachem”). Magenta and Bachem may be referred to individually as a
“Party” or collectively as the “Parties.” 
 RECITALS 

WHEREAS, Magenta is engaged in the development and research of certain pharmaceutical products and requires assistance in the development and
manufacture of active pharmaceutical ingredients for its clinical trials; and 
 WHEREAS, Bachem is a contract manufacturer that possesses
the necessary technical capabilities and operates pharmaceutical process development facilities for both the development and manufacture of pharmaceutical products used in clinical trials, as required by Magenta; and 

WHEREAS, Magenta desires Bachem to provide the Services and manufacture the Products specified in Project Plans (as defined below); and 

WHEREAS, Bachem is willing to provide the Services, manufacture the Product, and fulfill the Project Plans on the terms and conditions set
forth below. 
 NOW, THEREFORE, in consideration of the mutual promises contained herein, and for other good and valuable consideration, the
receipt and adequacy of which each of the Parties does hereby acknowledge, the Parties, intending to be legally bound, agree as follows. 
 Section 1.
DEFINITIONS 
 As used herein, the following terms shall have the following meanings: 

1.1 “Affiliate” shall mean any corporation or other entity which controls, is controlled by, or is under common control with,
a Party to this Agreement. A corporation or other entity shall be regarded as hi control of another corporation or entity if it owns or directly or indirectly controls more than fifty percent (50%) of the voting stock or other ownership interest of
the other corporation or entity, or if it possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of the corporation or other entity or the power to elect or appoint fifty percent (50%) or more of
the members of the governing body of the corporation or other entity. 
 1.2 “Applicable Laws” means all relevant federal,
state and local laws, statutes, rules, regulations, and ordinances and industry standards and guidelines as in effect on the Effective Date or adopted thereafter and which are applicable to a Party’s activities hereunder in their respective
countries, including, without limitation, the applicable regulations and guidelines of the FDA and all applicable GMPs together with amendments thereto. 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 1.3 “Batch” means a specific quantity of Product that is intended to have
uniform character and quality, within specified limits, and is produced according to a single manufacturing order during the same cycle of manufacture. 

1.4 “CMC” shall mean (i) manufacturing process development for Product; (ii) all chemistry, manufacturing
and control procedures necessary for the manufacturing, testing and quality control release of Product; and (iii) sourcing and testing of all raw materials and components used in the production of any Product. 

1.5 “CXCR2 Ligand” means the specific sequence(s) defined in Appendix B. 

1.6 “Development Specifications” shall mean the requirements of all Applicable Laws and the procedures, process parameters,
analytical tests and other attributes and written specifications for the Development Work attached hereto as part of a Project Plan. 
 1.7
“Development Work” shall mean those development Services that are to be performed by Bachem hereunder and which may include work related to identifying, formulating, developing and demonstrating cost effective, reproducible Product
and manufacturing a feasibility Batch. 
 1.8 “DMF” means a Drug Master File as described in 21 C.F.R. §
314.420. 
 1.9 “Effective Date” has the meaning set forth in the introduction. 

1.10 “FDA” means the United States Food and Drug Administration or any successor entity thereto. 

1.11 “GMPs” shall mean current good manufacturing practices, including the regulations promulgated by the FDA under the United
States Food, Drug and Cosmetic Act, 21 C.F.R. Part 210 et seq., as amended from time to time, applicable guidance documents issued by the FDA, applicable documents developed by the International Conference on Harmonization (ICH)
to the extent that they are applicable to Product and the Parties hereunder. 
 1.12 “Governmental Authority” means any
court, including any political subdivision thereof, court instrumentality, or agency thereof, and any other federal, state, or public authority, domestic or foreign, exercising governmental powers and having jurisdiction over any activity of a Party
under this Agreement. 
 1.13 “IND” means an investigational new drug application relating to a Product, and includes such
applications submitted to the FDA and equivalent applications submitted to a Governmental Authority outside of the U.S. 
 1.14
“Latent Defect” means a defect which could have been detected (but was not) by the analytical test methods in operation at the date of shipment to Magenta, attributable to an act or omission of Bachem that causes a Product to fail
to conform to the Specifications, which may not be discoverable upon the inspection and testing which Magenta would have been expected to carry out in its ordinary course of business, but is discovered at a later time. 

  
 2 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 1.15 “Product” means the product to be developed or manufactured by Bachem
pursuant to a Project Plan. 
 1.16 “Project Plant(s)” means a mutually agreed to project plan, statement of work, quotation
or other ordering document that sets forth a description of the Services to be provided by Bachem, and related timeline(s), costs, and other relevant details, that references, and is expressly governed by this Agreement and is executed by an
authorized representative of each Party. Notwithstanding, the Parties acknowledge and agree that the quotations identified in Appendix A attached hereto are Project Plans, and are governed by this Agreement, even though they do not expressly
reference this Agreement. 
 1.17 “Services” means, with respect to a Project Plan, those services (including Development
Work and manufacture of Product) to be provided by Bachem, as described in such Project Plan. 
 1.18 “Specifications” means
the requirements of all Applicable Laws, the master batch record, current standard operating procedures and the procedures, process parameters, analytical tests and other attributes and written specifications for the Product attached hereto as part
of a Project Plan, which the Parties agree are necessary for the manufacture and release of the Product for use in clinical trials. The Parties recognize that specifications for Product for a specific Project Plan are likely to change during the
term of this Agreement, and the Parties agree to act in good faith and reasonably to effect such changes as may be required. Copies of such Specifications, as amended, shall be maintained by both Parties, and shall be incorporated into this
Agreement and the Quality Agreement (as defined below). 
 1.19 “Third Party” means any entity other than Magenta or Bachem.

 1.20 “U.S.” means the United States of America, its territories, commonwealths, and possessions, including the District
of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, Guam, and all other places under the jurisdiction thereof. 
 Section 2.
ENGAGEMENT OF BACHEM 
 Magenta hereby engages Bachem to perform the Services and manufacture the Product in accordance with the applicable Project
Plan(s) and in compliance with Applicable Laws and the terms and conditions set forth herein, and Bachem hereby accepts such engagement. Bachem will supply to Magenta all Product ordered by Magenta hereunder as set forth in the Project Plan and
related purchase orders. 
 Section 3. PROJECT PLANS 

3.1 Project Plans. All Project Plans entered into after the Effective Date shall be added to Appendix A after execution by the
Parties of a written amendment in the form of the “Amendment to Appendix A”, attached hereto (the “Amendment”). There shall be no limit to the number of Project Plans that may be added to Appendix A and governed by
the terms and conditions of this Agreement. In the event of a conflict between the terms of a Project Plan or any attachments thereto or any purchase order issued in connection therewith and this Agreement, the terms of this Agreement will govern.

  
 3 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 3.2 Content of Project Plans. Each Project Plan shall include a description of the
Services to be provided, including, if applicable, the Development Work to be completed, the Product to be manufactured, relevant Development Specifications, relevant Specifications, deliverables, a corresponding budget, a schedule for completion of
the Project Plan (which may be set forth for the entire Project Plan or stages thereof), a fee and payment schedule, delivery terms, and such other information as the Parties determine is necessary for Bachem to perform the Services and manufacture
the Product. Magenta may amend any Project Plan before its completion, subject to prior written approval by Bachem, which approval shall not be unreasonably withheld. If such amendment entails additional expenses that will be incurred by Bachem, the
Parties agree to reconsider in good faith the budget and the payment and fee schedule. 
 3.3 Materials and Equipment. Unless
otherwise agreed by the Parties in writing or specified in the applicable Project Plan, Bachem shall supply all materials and standard processing and manufacturing equipment needed to provide the Services and manufacture the Product in accordance
with this Agreement and the applicable Project Plan, at its sole cost and expense. 
 3.4 Change Orders. In the event that Magenta
requests or requires Bachem to perform services that are outside the scope of this Agreement, or Magenta desires to amend a Project Plan, such changes must be mutually agreed upon by the Parties in a written change order (a “Change Order”)
prior to the provision of said services or implementation of such amendment by Bachem. Each such Change Order constitutes an amendment to the Agreement and/or the applicable Project Plan, and thereafter the services or amendments set forth therein
shall be deemed Services hereunder. 
 3.5 Project Manager. With respect to each Project Plan, an employee of Bachem shall be
appointed as project manager by Bachem (the “Project Manager”). The Project Manager shall be the primary contact for Magenta and shall timely address all issues and concerns raised by Magenta, as well as provide to Magenta all
information requested by Magenta concerning this Agreement or the Services. The Project Manager shall not be replaced without advanced written notice to Magenta. In the event that Bachem becomes aware that the Project Manager plans to leave the
employment of Bachem or shall be unable to complete the Services due to dismissal, death or disability, it shall give immediate written notice of the same to Magenta so as not to impact ongoing manufacture or supply. Should Magenta not be satisfied
with the services of Project Manager, Magenta may give notice of the same to Bachem and Bachem will assign a suitable replacement who is reasonably acceptable to Magenta within [***] of such notice. 

Section 4. COMPENSATION 
 4.1
Generally. The fees to be paid to Bachem in connection with the Services shall be set forth in reasonable detail in each Project Plan. Bachem represents that it has included all of its costs, fees and expenses, including administrative
overhead, in calculating the fee for the Services budget attached hereto as part of the applicable Project Plan, and that Magenta shall not be liable for or be charged for any other costs, fees or expenses of Bachem. No line item in any Project Plan
budget shall be exceeded by Bachem without the prior written consent of Magenta. 

  
 4 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 4.2 Invoicing and Payment. Unless specifically agreed otherwise in writing by the
Parties, including as agreed in a Project Plan, (i) all invoices and payments hereunder shall be in U.S. Dollars, (ii) payments will be made payable to Bachem at the address set forth in applicable Project Plan(s), and
(iii) all undisputed payments shall be made within [***] of receipt of invoice by Magenta. 
 4.3 Taxes. All prices are
stated exclusive of VAT (or equivalent tax) that may or may not become due according to Applicable Law. Each Project Plan shall set forth an estimate of VAT that may become due thereunder and Bachem shall notify Magenta within a reasonable period of
time upon becoming aware of a material deviation from such estimate. 
 4.4 Bachem’s Fees for Performance of Services.
Bachem’s fees for the performance of Services represent the entire cost for the provision of such Services. Magenta shall not be charged for any Service or deliverable that is not performed or delivered, as the case may be, in accordance with
this Agreement or the applicable Project Plan(s). 
 Section 5. BACHEM REPRESENTATIONS, WARRANTIES, AND CERTAIN COVENANTS 

5.1 Authority. Bachem represents and warrants mat it has full authority to enter into this Agreement and there is no provision contained
in any other agreement to which it is party or arrangement or obligation to which it is bound that prohibits or restricts it from entering into or performing under this Agreement. 

5.2 Services. Bachem shall provide the Services in accordance with each Project Plan. Bachem will perform all Services in accordance
with this Agreement and the agreed upon Specifications. All Products shall be packaged, labeled and shipped in accordance with this Agreement, the applicable Project Plan and all Applicable Laws. Bachem and its employees and agents have, and will
continue to have, the knowledge, experience, facilities, equipment and skill to provide, and will provide, the Services in a professional and timely manner. Services will conform to consistently high standards of workmanship and the specifications
applicable to each Project Plan. 
 5.3 Material/Supplies. In situations where Magenta provides materials or supplies to Bachem in
connection with this Agreement and/or a Project Plan(s), Bachem shall use such materials and supplies only in accordance with the applicable Project Plan for which it was received, and Bachem shall not use it for any other purpose. Bachem shall be
responsible for all such materials and supplies provided by Magenta while they are in Bachem’s control or the control of its agents, and Bachem shall promptly, at Magenta’s direction, destroy or return to Magenta all unused quantities of
its materials and supplies provided by Magenta. For the avoidance of doubt, Magenta shall retain title to all of its materials and supplies, including any API or intermediates, while it is in Bachem’s facility (as of the Effective Date, this
facility will be Haupstrasse 144, CH-4416, Bubendorf, Switzerland). Magenta shall be responsible for all such materials and supplies until delivered to Bachem at its facility. Any such materials or supplies shall be delivered in a timely manner and
in accordance with the shipping instructions and specifications to be agreed upon by the Parties. 

  
 5 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 5.4 Deliverables. Each deliverable (including Product) developed or produced in
connection with a Project Plan and this Agreement shall conform to the Specifications. The Development Work, as described in the Project Plan, shall conform to the Development Specifications. Bachem shall warrant compliance with the agreed
acceptance criteria together with the results as reported on the Certificate of Analysis in conjunction with the analytical methods at the time of the release of Product. In no event shall Bachem be liable for any defects that could not have been
detected by Bachem with the analytical test methods in operation at the date of product release. For reasons of clarity, the Parties acknowledge and agree that it shall remain solely the responsibility and liability of Magenta to determine the
suitability of the Product for any intended or specific use of the Product. Bachem makes no expressed or implied guarantees, warranties or undertakings as to the use of the Product for an intended or specific purpose or use. 

5.5 Third Party IP. Bachem will not knowingly infringe or misappropriate any third party intellectual property rights in connection with
the performance of its obligations hereunder. Materials delivered by Magenta to Bachem will not, to Magenta’s knowledge, infringe any third party intellectual property rights. 

5.6 No Encumbrance. Bachem hereby (i) acknowledges and agrees that neither it, nor any of its affiliates or subsidiaries, nor any
of its or their directors, officers, employees and agents has any interest in Magenta Pre-Existing Intellectual Property or Magenta Developed Intellectual Property (each as defined below) and
(ii) covenants that it will not lien or encumber, or otherwise cause, permit or consent to the granting of a lien or encumbrance of Magenta Pre-Existing Intellectual Property or Magenta Developed
Intellectual Property. 
 5.7 Books and Records. Bachem shall maintain true, complete and accurate books, records, test and laboratory
data, reports and all other information relating to Services performed and Product manufactured under this Agreement, including all information required to be maintained by Applicable Laws. 

5.8 Disclosures. Upon Magenta’s reasonable request, Bachem shall also provide all information to Magenta that is specifically
related to the Product and Services, including any information which is reasonably required to comply with any disclosure requirements of regulatory authorities. 

5.9 Regulatory Inspections. Bachem shall make its facilities and all records relating to the Product, and Services related thereto,
available to the FDA or other regulatory authorities, as mutually agreed by the Parties, and shall notify Magenta immediately if the FDA or any other regulatory authority begins or schedules an inspection of Bachem’s records, facilities, or
manufacturing processes that are solely related to the Product or the Services related thereto. Bachem shall provide Magenta access to any documentation related to or resulting from each such inspection in accordance with the provisions of the
Quality Agreement. If a regulatory authority in connection with a preapproval inspection of the Product inspects the Bachem facility used for production of Product, Bachem will notify Magenta in writing within [***] after learning of the inspection
unless otherwise specified in the Quality Agreement. If an FDA Form 483 (or an equivalent foreign regulatory authority form) is issued in connection with the Product, Bachem will provide its proposed response to such Form 483 (or equivalent form) to
Magenta 

  
 6 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 
for Magenta’s review and (non-binding) input in accordance with the provisions of the Quality Agreement. Bachem will consider in good faith any comments and suggestions provided by Magenta
with respect to such proposed response if received by Bachem in a timely manner. For the avoidance of doubt, nothing in this Agreement shall hinder Bachem from providing its answers to regulatory authorities within the timelines required by such
authorities. 
 5.10 Report of Noncompliance. In the event that an employee or agent of Bachem who is working on a Project Plan fails
to comply with Applicable Laws, this Agreement or any applicable agreement as the same relates to the Services, and such failure is discovered by or comes to the attention of Bachem’s COO or a supervisor of Bachem with respect to the applicable
Project Plan, Bachem will immediately notify Magenta in writing. Appropriate action will be taken by Bachem at the direction of Magenta, after Bachem consults in good faith with Magenta, as to what actions might be undertaken by Bachem in view of
the particular facts surrounding such noncompliance. 
 5.11 Information. Upon request, Bachem shall provide to Magenta access to all
information in Bachem’s control that relates to the [***], Product and/or the Project Plan within a reasonable period of time. Copies of batch records will be provided on an electronic platform for a period of [***], or another period of time
by mutual agreement of the Parties, and with restricted access rights only. 
 5.12 Debarment. Bachem hereby certifies that it does
not and shall not employ, contract with or retain any person directly or indirectly to perform Services under this Agreement or any Project Plan if such person is or has been debarred under 21 U.S.C. 335a (a) or (b) or other equivalent laws,
rules, regulations or standards of any other relevant jurisdiction. Upon written request of Magenta, Bachem shall, [***], provide written confirmation that it has complied with the foregoing obligation. Bachem agrees to immediately disclose in
writing to Magenta if any employee or agent is debarred, or if any action or investigation is pending or, to the best of Bachem’s knowledge, is threatened in relation to the debarment of Bachem or any person performing Services in connection
with this Agreement. 
 5.13 Restrictions on Bachem. Bachem agrees to supply the Product(s) identified in each applicable Project Plan
to Magenta pursuant to the terms and conditions of this Agreement and any applicable Project Plans. During the Initial Term and any Renewal Term, Bachem agrees not to sell, supply or otherwise distribute CXCR2 Ligand for any clinical or commercial
use to any Third Party without Magenta’s prior written consent, for so long as Bachem remains Magenta’s primary supplier of CXCR2 Ligand for the Initial Term and any Renewal Term. 

5.14 Changes by Bachem. Bachem shall not make any major changes to the Development Specifications, the Specifications or any
manufacturing process with a potential to adversely impact the quality of the Product in connection with a Project Plan without the prior written consent of Magenta. Notwithstanding, Magenta acknowledges and agrees that changes will be required for
the development of the Product. Thus, during the development phase of a Product and up to the completion of the full validation of the manufacturing process of a Product, some quality assurance standards may not be fully implemented or applied in
the manufacturing, release and supply of such Product. These limited quality assurance standards may relate to (i) the manufacturing and testing procedures in development and/or (ii) formalized

  
 7 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 
Product specific procedures that may not be in place and generic procedures that may be applied instead and/or (iii) change control that may be less stringent during development and/or
(iv) Product specific validation may not be available. However, Bachem will manufacture the Product according to applicable GMP guidelines as defined in the Quality Agreement. 

5.15 DMF/Amendment. Upon Magenta’s reasonable request and order, Bachem will compile a DMF for the Product in cooperation and
mutual agreement with Magenta. Bachem hereby grants to Magenta, at no additional cost, reference rights to the DMFs, which are necessary to support Magenta’s regulatory submissions with respect to the Product. Bachem shall provide reasonable
advance written notice to Magenta prior to amending any Bachem DMF that is referenced in a filed IND of Magenta or in a proposed IND filing of Magenta. Bachem will, at Magenta’s expense, provide reasonable assistance as necessary so that the
FDA (and/or equivalent foreign regulatory authority) can reference the relevant DMF. Bachem shall not permit the FDA or any other regulatory authority to reference its DMF in order to permit a Third Party to develop, manufacture or commercialize
CXCR2 Ligand or any products that incorporate CXCR2 Ligand or compete with CXCR2 Ligand. In the event that the Parties agree that Bachem will not file a DMF in connection with a Project Plan, Bachem shall instead fully cooperate with Magenta, and
provide a quote (similar to the compiling of a DMF) to provide all information, data, and rights of reference reasonably required by Magenta in connection with its regulatory and governmental filings related to Product. 

5.16 Waste Disposal. Bachem shall generate, handle, store, ship and dispose of all wastes associated with its manufacture of Product in
accordance with Applicable Laws. Notwithstanding the foregoing sentence, if any specially regulated waste must be removed pursuant to a given Project Plan, such specially regulated waste and the process for its removal shall be expressly set forth
in such Project Plan. If the specially regulated waste is solely attributable to Magenta’s Product and the Specifications and instructions for production of such Product, then unless the Parties otherwise agree, Magenta shall be responsible for
the reasonable costs associated with the removal of such specially regulated waste. Such costs shall be included in the Project Plan or, if not specified therein, included in the price of the Services and Product. 

5.17 Audits. Magenta and its agents and designees shall have the right to audit Bachem’s facilities, systems, records, procedures,
and documentation related to this Agreement. In connection with any such audit, Bachem shall also provide Magenta access to its personnel. Magenta may conduct no more than one (1) technical visit and one (1) quality assurance audit per
year, unless there is cause for an additional audit (i.e., a technical issue or quality issue). Such audits may be conducted upon reasonable notice during the term of this Agreement and for [***] thereafter.
On-site technical discussions may also be requested and held at mutually agreeable times. 
 5.18 Person-In-Plant. If reasonably requested by Magenta, at a mutually agreed day and time, Bachem will permit and provide working space for Magenta to staff one person on location at Bachem’s premises, limited
to no more than [***] days, during preparation for manufacturing and packaging of the Product. Such person shall be given reasonable access to all records, facilities and personnel working on any Services or Project Plans for the purpose or
providing advice, coordinating reviews, approvals or any other actions required to ensure compliance with this Agreement to the extent that it does not compromise the confidentiality of other customers. 

  
 8 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 5.19 Quality Agreement. As reasonably required by Magenta in connection with Product
manufacturing activities hereunder, Bachem shall enter into a written quality agreement with Magenta (the “Quality Agreement”). 

Section 6. ADDITIONAL PRODUCT SUPPLY TERMS 

6.1 Delivery. Unless otherwise agreed to between the Parties, delivery terms shall be DDP (Incoterms 2010) Magenta’s facility
located at 50 Hampshire Street, 8th Floor, Cambridge, MA 02139, or such other destination as Magenta may instruct in writing, at which time risk of loss and responsibility for Product will
transfer to Magenta. Bachem shall assume all risk and responsibility for handling, storing, rotating stock, packaging, loading and shipping all Product in accordance with applicable Incoterms. Bachem shall ship the Product in accordance with the
applicable Project Plan. Delivery shall occur on the delivery dates set forth in each Project Plan and any related purchase orders or as otherwise agreed to in writing by the Parties. 

6.2 Acceptance and Rejection of Products. 

(a) Promptly following receipt of Product, Magenta shall have the right but not the obligation to test such Product to determine compliance
with the Specifications. Magenta shall have [***] after receipt of the Product to notify Bachem in writing of any rejection of Product based on a sufficiently documented claim that the Product fails to meet the Specifications. In the event that
Magenta does not inform Bachem within the [***] period that the Product does not meet the Specifications, Magenta shall be deemed to have accepted the Product. If there is no dispute between the Parties over a claim that the Product fails to meet
the Specifications, Bachem shall (i) replace or (ii) with Magenta’s prior written consent, reprocess or rework the rejected Product within an agreed upon time frame, after the notice of such rejection, and in any case as
soon as reasonably possible after receiving such notice, provided that Magenta shall, at Bachem’s expense, provide to Bachem sufficient quantities of supplies required to be supplied by Magenta under the relevant Project Plan, at no additional
cost to Magenta (including transportation costs), and Bachem shall make arrangements with Magenta for the return or disposal of any rejected Product, such return shipping or disposal charges to be paid by Bachem. In the event of a discrepancy
between Magenta’s and Bachem’s test results such that one Party’s test results fall within relevant Specifications and the other Party’s test results fall outside the relevant Specifications, or there exists a dispute between the
Parties over the extent to which such failure is due to acts or omissions of Bachem, the Parties shall cause an independent GMP laboratory or appropriate experts promptly to review records, test data and perform comparative tests and/or analyses on
samples of the alleged defective Product. Such independent laboratory shall be mutually agreed upon by the Parties. The independent laboratory’s results shall be in writing and shall be final and binding save for manifest error. Unless
otherwise agreed to by the Parties in writing, the costs associated with such testing and review shall be borne by the Party against whom the independent laboratory rules. 

  
 9 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 (b) If Bachem shall fail to deliver to Magenta the full quantity of the Product as specified
in a Project Plan by the delivery date specified therein, for any reason whatsoever other than a breach of this Agreement by Magenta, then at Magenta’s election: (i) Bachem shall be relieved of any obligation to deliver the
remaining quantity of the Product or (ii) Bachem shall deliver the remaining quantity of the Product as soon as reasonably possible after the date Magenta notifies Bachem of such election. Magenta and Bachem will agree upon the time
period to deliver the remaining Product allowed under clause (ii) [***] of the missed delivery date (or, if applicable, the date on which Bachem notifies Magenta that such delivery will be late). 

6.3 Latent Defects; Contamination. 

(a) As soon as either Party becomes aware of a Latent Defect in any lot of Product, but in no case later than (i) within one
(1) week after reaching such awareness or (ii) the end of the indicated retest period for the lot with the Latent Defect, whichever is earlier, it shall immediately notify the other Party. Bachem shall be fully responsible
for all Latent Defects. At Magenta’s election, the lot or batch with the Latent Defect shall be deemed rejected as of the date of such notice and the provisions of Section 6.2 shall apply. 

(b) Bachem shall be fully responsible for any Product and/or Product-related supplies that are adulterated, contaminated, damaged or destroyed
while in Bachem’s control. Bachem agrees, at the election of Magenta and in addition to any other remedies Magenta may have, to promptly replace such Product and/or Product-related supplies (as the case may be) or refund to Magenta the value of
the Product or Product-related supplies. 
 6.4 Stability, Record Keeping. Bachem shall retain such Product stability samples and keep
manufacturing records, and any other records set forth in a Project Plan, for [***] from the expiration or termination of this Agreement. Bachem shall make accessible for review by Magenta during an audit or inspection, or following Product release
by Bachem’s Quality Assurance Department, either onsite or on an electronic platform with restricted access rights only (as reasonably requested by Magenta), at a mutually agreeable time, all specific Batch and lot records relevant to
Bachem’s performance hereunder, including written investigations of any deviations and “out-of-specification” events that may have been generated from
manufacturing, packaging, inspection, or testing processes. 
 6.5 CMC Responsibilities; Regulatory Submissions; Permits. Bachem shall
be responsible for obtaining and maintaining, at its sole expense, any facility or other licenses or permits, and any regulatory approvals, necessary for the manufacture of Product, supply of Product, and performance of Services, all in accordance
with the terms and conditions of this Agreement, At Magenta’s request and expense, Bachem shall also compile the regulatory submissions documentation for the Product (i.e. CMC documentation and DMF) as reasonably requested by Magenta, including
permitting the FDA to reference Bachem’s DMF, once it is available, in connection with Magenta’s IND. 
 6.6 Recall. In the
event of a recall of Product, Magenta shall be responsible for coordinating such recall. Magenta promptly shall notify Bachem if any Product is the subject of a recall and, to the extent required by Bachem, provide Bachem with a copy of all
documents relating to such recall. Bachem shall cooperate fully with Magenta in connection with any recall. Magenta shall be responsible for all of the costs and expenses of such recall, except to the extent

  
 10 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 
that Bachem is determined to be responsible for such recall. In such case, Bachem shall be responsible for such costs and expenses. Such determination of responsibility may be made by the
governmental agency involved or by mutual agreement by the Parties following examination and review of all records pertinent to the manufacture of the Product subject to such recall. In case of shared responsibility, the costs should be allocated in
accordance with each Party’s share of responsibility. 
 Section 7. TERM AND TERMINATION 

7.1 Term. This Agreement shall commence on the Effective Date and shall extend for a period of Five (5) years thereafter
(“Initial Term”), unless this Agreement is terminated earlier as provided herein or is extended by mutual written agreement of the Parties. This Agreement may be renewed for additional periods of one (1) year (each such
additional period, a “Renewal Term”) unless either Party provides notice of nonrenewal upon not less than [***] prior written notice to the other Party. Notwithstanding the foregoing, each Project Plan may have separate term and
termination provisions, so long as the term of any Project Plan does not extend beyond the Initial Term or a subsequent Renewal Term. 
 7.2
Termination. This Agreement or any Project Plan may be terminated: 
 (a) by Magenta for any reason upon [***] written notice
to Bachem; 
 (b) by either Party if the other Party materially breaches a provision of this Agreement or a Project Plan, and fails to cure
such breach within [***] following receipt of written notification of such breach from the non-breaching Party; 

(c) by either Party, immediately, if the other Party becomes insolvent, is dissolved or liquidated, makes a general assignment for the benefit
of its creditors, or files or has filed against it, a petition in bankruptcy that is not dismissed within sixty days after filing, or has a receiver appointed for a substantial part of its assets; and 

(d) by a Party or the Parties pursuant to Section 13. 

In the event of termination pursuant to Section 7.2(a) or a termination by Bachem pursuant to Section 7.2(b), Bachem shall be compensated for
Services rendered up to the date of termination. In the event of any other termination, the Parties shall negotiate in good faith to determine the appropriate amount to be paid by Magenta to Bachem (or refunded to Magenta by Bachem, as the case may
be), in light of the circumstances of such termination, in compensation for all Services rendered in accordance with this Agreement. In the event of Bachem’s inability to supply the Product or a material breach by Bachem pursuant to
Section 7.2(b), Bachem shall provide, without additional charge to Magenta, sufficient information and technology pertaining to its Services to Magenta and/or its technically competent designee, such that Magenta and/or its technically
competent designee are enabled to continue Development Work and manufacture of the Product. The termination of any Project Plan may be independent of the termination of this Agreement. 

  
 11 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 7.3 Regulatory information and Compounds. On or before the effective date of any
termination or expiration of this Agreement or upon the written request of Magenta, Bachem shall promptly transfer to Magenta all compounds and other materials and supplies provided to Bachem by or on behalf of Magenta in connection with this
Agreement, as well as all works-in-process and raw materials purchased under a Project Plan. Upon the expiration or termination of this Agreement or upon the written
request of Magenta, Bachem will also compile CMC documentation as provided for in the applicable Project Plan, which will contain all information necessary for Magenta for regulatory and manufacturing purposes related to the Product. The CMC
documentation would also contain the information required for any competent Third Party manufacturing to assume manufacturing of the Product independently, if Magenta desires to transfer the process. Upon the request of and at the expense of
Magenta, after termination of this Agreement, Bachem agrees to reasonably assist Magenta in identifying Third-Party manufacturers of the Product. If such termination is due to Bachem’s inability to make the Product, or a material breach by
Bachem pursuant to Section 7.2(b), Bachem will provide such assistance without charge. 
 7.4 Project Plans in Progress.
In the event of any termination or expiration of this Agreement, Bachem shall, upon the request of Magenta and notwithstanding the effective date of any termination or expiration, complete any Project Plans involving the manufacture of Product that
were accepted by Bachem prior to such date, and Magenta shall pay Bachem for any Product produced or services completed, in accordance with the terms of the applicable Project Plans and this Agreement. If this Agreement is terminated by Magenta
pursuant to Section 7.2(a) or by Bachem pursuant to Section 7.2(b) or (c), Magenta shall also pay to Bachem amounts for any services that cannot be reasonably stopped at the time of termination; provided, that, Bachem will take all
reasonable steps necessary to wind down such work as promptly as practicable. 
 7.5 Survival. The rights and obligations of each
Party which by their nature survive the termination or expiration of this Agreement shall survive the termination or expiration of this Agreement, including Sections 4.2, 5, 6.3-6.6, 7.2-7.5, 8, 9, 10, 11, 12, 14, 15.1, 15.4-15.8, 15.10, 15.11 and 15.12. In addition, Bachem hereby acknowledges that neither expiration nor termination of this Agreement shall
affect in any manner Magenta’s right to manufacture and sell, or have manufactured and sold, the Product. 
 Section 8. INTELLECTUAL PROPERTY

 8.1 Magenta Pre-Existing Intellectual Property. All intellectual property (including
trademarks), including all data, information, know-how, reports and any and all related documentation, which are developed, generated or derived, directly or indirectly by or on behalf of Magenta prior to the
Effective Date (“Magenta Pre-Existing Intellectual Property”) shall remain the sole property of Magenta. 

8.2 Bachem Intellectual Property. All intellectual property (including trademarks), including all data, information, reports,
manufacturing know-how and any and all related documentation, which are (a) developed, generated or derived, directly or indirectly by or on behalf of Bachem prior to the Effective Date or (b)
any manufacturing know-how developed or generated by Bachem that is generally applicable to the field of peptide manufacturing and not specific to the Product or Magenta’s Confidential Information (such
items under the foregoing clauses (a) and (b), collectively, “Bachem Intellectual Property”), shall remain the sole property of Bachem. In the event that any Bachem Intellectual Property is incorporated into any

  
 12 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 
deliverable (including Magenta Developed Intellectual Property (including Product)) or is otherwise necessary to fully exploit such deliverable, Bachem hereby grants to Magenta a perpetual,
irrevocable, nonexclusive, worldwide, paid up, royalty-free license under such Bachem Intellectual Property (with the full right to sublicense directly or indirectly through multiple tiers) to (i) copy, distribute, display, perform and
create derivative works of the Bachem Intellectual Property, in whole or in part; and (ii) to use Bachem Intellectual Property and/or practice the subject matter thereof, in each case solely in connection with manufacturing, marketing,
promoting, using, selling, offering for sale, importing or distributing such deliverable (e.g., Product). Without limiting the foregoing, Magenta may use and disclose Bachem Intellectual Property to the extent necessary in connection with the
prosecution, maintenance and enforcement of Magenta Developed Intellectual Property. 
 8.3 Magenta Data. All data, images,
information, documents, records in whatever form obtained, developed, recorded or compiled (i) in connection with this Agreement or any Project Plan that relates to the Development Work or the Product, including, but not limited to, its
development, manufacture or use, expressly excluding any Bachem Intellectual Property, or (ii) based upon or utilizing Magenta Confidential Information (collectively, “Magenta Data”) are and shall remain the sole and
exclusive property of Magenta, and will be gathered, stored, secured, managed and maintained by Bachem in accordance with Applicable Laws. Bachem agrees to take such further acts as may be requested by Magenta in order to evidence the foregoing.
Promptly upon the expiration or termination of this Agreement or any Project Plan, and otherwise upon Magenta’s request, Bachem will promptly provide originals or a copy (as applicable) of all Magenta Data to Magenta in a form acceptable to
Magenta, and, to the extent that Magenta so requests. Availability of batch records shall be provided as set forth in Section 5.11. At Magenta’s request, Bachem will destroy all remaining Magenta Data in Bachem’s possession or
under Bachem’s control, so long as not in contravention of Applicable Laws. Bachem will not utilize Magenta Data for any purpose other than the performance of Services, and will cease use of any Magenta Data after expiration or termination of
this Agreement. Notwithstanding anything herein to the contrary, Bachem may retain any Magenta Data in electronically stored archives that cannot be deleted, subject to Bachem’s document retention policies and to the terms of confidentiality
and non-use set forth in this Agreement. 
 8.4 Magenta’s Developed Intellectual Property. Any invention (whether patentable or
not), discoveries, improvements, works-of-authorship or other intellectual property made, conceived or reduced to practice by Bachem in connection with its performance
under this Agreement or any Project Plan, which expressly excludes Bachem Intellectual Property (“Magenta Developed Intellectual Property”), shall be exclusively owned by Magenta. For the avoidance of doubt, Magenta Developed
Intellectual Property includes Magenta Data. Bachem hereby assigns, and agrees to assign, to Magenta all of its right, title and interest to and in any Magenta Developed Intellectual Property, including all related intellectual property rights.
Magenta grants to Bachem a limited, non-exclusive license to use any Magenta Developed Intellectual Property to manufacture and release the Product for Magenta in accordance with the terms and conditions of this Agreement and any applicable Project
Plan. 

  
 13 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 8.5 Disclosure and Assignment. With respect to all Magenta Developed Intellectual
Property, Bachem agrees (i) to disclose the same promptly to Magenta; (ii) to execute documents evidencing the rights of Magenta set forth in this Section 8; and (iii) upon the request of Magenta and at the sole
expense, discretion and exclusive control of Magenta, to apply, or to assist and cooperate with Magenta in applying for, letters patent or like corresponding legal protection of any of the foregoing in the United States and all foreign countries
(and for any extension, continuation, validation, reissue or renewal thereof). For that purpose, Bachem shall, and shall cause its employees and agents to, execute all papers necessary therefor, including assignments to Magenta or its nominee,
without consideration, and also agrees without further consideration, but at Magenta’s expense, to provide such information as may be required by Magenta and to assist Magenta, or its agents or designees, in the preparation and prosecution of
any such patent application, the enforcement of any such resulting patent and the intellectual property protection of any such invention or discovery. 

Section 9. CONFIDENTIALITY 
 9.1
Confidentiality Agreement. The Parties agree that the terms and provisions of this Agreement shall supersede all terms and provisions of that certain Confidentiality Agreement between the Parties dated February 9, 2016 (the
“Confidentiality Agreement”) and, as of the date hereof, the Confidentiality Agreement is hereby terminated and of no further force or effect. 

9.2 Confidential Information. As of the Effective Date, the Parties agree to treat all Confidential Information (as described herein)
acquired by either of them from the other under this Agreement as being secret and confidential, and each Party agrees that it shall not, at any time, without the express written consent of the other Party, disclose to any third party any
Confidential Information. Each Party agrees that it shall use the other Party’s Confidential Information solely to conduct the activities contemplated under this Agreement and for no other purpose. Confidential Information of a Party shall only
be disclosed to the those employees, agents and Affiliates of the other Party who have a need to know such Confidential Information and only to the extent necessary in order to fulfill the relevant Party’s obligations under this Agreement, who
have been informed of the confidential nature of such information and who are obligated by written agreement to comply with confidentiality provisions no less restrictive than those set forth in this Agreement. Notwithstanding the foregoing, Magenta
may disclose Confidential Information of Bachem relating to a Project Plan(s), Services, or the manufacture of Product to entities with whom Magenta has or may have a marketing and/or development collaboration or partnership and who have a specific
need to know such Confidential Information and who are bound by written agreements which contain restrictions regarding disclosure and use of such Confidential Information no less restrictive than those set forth herein. Each Party further agrees to
take such reasonable precautions as it normally takes with its own Confidential Information to prevent any unauthorized disclosure or use of such Confidential Information. For the purposes of this Agreement, “Confidential
Information” shall mean all confidential or proprietary materials or information not generally available to the public that is confidential and proprietary to Magenta or Bachem (as the case may be). Magenta’s Confidential Information
includes, but is not limited to, Magenta Pre-Existing Intellectual Property, Magenta Developed Intellectual Property, confidential information provided to Bachem prior to the date hereof, all information
regarding Magenta’s materials, processes, know-how, formulations, analytical procedures, clinical procedures, its INDs and any other regulatory filings, other information related to the Product or any
other product that may or will be under development by Magenta and any other technical or business information of Magenta (in each case, expressly excluding 

  
 14 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 
Bachem Intellectual Property). Bachem’s Confidential Information includes, but is not limited to, Bachem Intellectual Property, and all information regarding its business, customers, and
price lists. As used in this Section 9, the Party in receipt of Confidential Information is the “Recipient” and the Party disclosing such information is the “Disclosing Party.” 

9.3 Exceptions. The provisions of Section 9.2 shall not apply to any information disclosed hereunder that: 

(a) was known to Recipient prior to its date of disclosure by the Disclosing Party as evidenced by Recipient’s written records; 

(b) is disclosed lawfully to Recipient either before or after the date of the disclosure by the Disclosing Party, without an obligation of
confidentiality by a Third Party rightfully in possession of such information; 
 (c) is published or generally known to the public, either
before or after the date of disclosure by the Disclosing Party, through no act or omission on the part of Recipient; 
 (d) is independently
developed by Recipient without reference to or in reliance upon the Confidential Information of the Disclosing Party; and 
 (e) is required
to be disclosed by Recipient to comply with Applicable Laws, to defend or prosecute litigation, or to comply with governmental regulations; provided that Recipient provides prior written notice of such disclosure to the Disclosing Party and
cooperates with the Disclosing Party to take reasonable and lawful actions to avoid and/or minimize the degree of such disclosure. 
 9.4
Return of Confidential Information. Upon request by the Disclosing Party, Recipient shall promptly return to the Disclosing Party the originals and all copies of any Confidential Information then in the Recipient’s possession or under
the Recipient’s control. Notwithstanding the foregoing, the Recipient may retain one (1) copy of such Confidential Information for legal archival purposes, provided that such copy shall be kept confidential after the termination or
expiration of this Agreement. 
 9.5 Handling and Reconstruction of and Access to Confidential Information. Bachem will establish and
maintain rigorous safety and facility procedures, data security procedures and other safeguards against the destruction, loss, or alteration of Magenta’s Confidential Information in the possession of Bachem. Bachem will be responsible for
developing and maintaining procedures for the recovery and reconstruction of lost Confidential Information. Bachem will correct or remedy, at Magenta’s request and sole discretion and at no charge to Magenta, any destruction, loss or alteration
of any of Magenta’s Confidential Information that occurs while such Confidential information is under the control of Bachem. Upon reasonable request by Magenta, Bachem will promptly retrieve any portion of Magenta’s Confidential
Information reasonably specified by Magenta. Magenta shall have the right to review and retain the entirety of, all computer or other files containing Magenta’s Confidential Information. Bachem shall not withhold from Magenta any of
Magenta’s Confidential Information as a means of resolving a dispute. 

  
 15 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 9.6 Equitable Relief. In the event of a breach or threatened breach by a Party of any
provision of Section 8 or 9 hereof, the other Party shall be authorized and entitled to obtain from any court of competent jurisdiction equitable relief, whether preliminary or permanent, including specific performance, in addition to any
other rights or remedies to which such Party may be entitled in law or equity. 
 9.7 Survival. The obligations of confidentiality set
forth in this Agreement shall survive its termination or expiration for a period of [***]. 
 Section 10. INSURANCE 

Bachem shall, during the Initial Term and any Renewal Terms, and [***] after the expiration of the last Product is delivered, obtain and
maintain, at its own cost and expense and from a qualified insurance company, comprehensive general liability insurance including, but not limited to, contractual liability coverage and standard product liability coverage in an amount commensurate
with industry standards. At Magenta’s request, Bachem shall provide Magenta with proof of such coverage. Bachem shall provide, and shall cause its Affiliates and sublicensees who perform activities in connection with the manufacture of Product
to provide, to Magenta, upon its reasonable request, a statement of coverages, amounts of insurance, and deductibles, and a copy of all policies including clauses within the policies that the insurance company has a duty to defend and indemnify.

 Section 11. INDEMNIFICATION 

11.1 By Magenta. Magenta agrees to indemnify, defend and hold harmless Bachem, its Affiliates, directors, officers, employees and agents
from and against damages finally awarded or finally paid in settlement of any and all losses (including attorneys’ fees and expenses), whether arising as a result of third party claims or a claim between the Parties (“Losses”) arising
out of or in connection with (i) the use or sale of the Product (ii) Magenta’s labeling or improper handling and storage of Product, or (iii) any gross negligence, willful misconduct or misrepresentation by
Magenta or material breach by Magenta of this Agreement, except to the extent that such Losses are attributable to the gross negligence or willful misconduct of or breach of this Agreement by Bachem. 

11.2 By Bachem. Bachem shall indemnify, defend and hold harmless Magenta, its Affiliates, directors, officers, employees and agents from
and against Losses arising out of or in connection with: (i) any Product that does not meet the Specifications, (ii) Bachem’s labeling or improper manufacturing, handling, use or storage of a Product, (iii) any gross
negligence, willful misconduct or misrepresentation by Bachem or material breach by Bachem of this Agreement, or (iv) any Latent Defects in a Product, except to the extent that such Losses are attributable to the gross negligence or
willful misconduct of or breach of this Agreement by Magenta. 
 11.3 Limitation of Liability. NEITHER PARTY SHALL BE LIABLE, WHETHER
BASED ON CONTRACT LAW, TORTS OR ANY OTHER AREA OF LAW, FOR ANY INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY RELATED TO THIS AGREEMENT OR ITS PERFORMANCE AND THE MAXIMUM TOTAL LIABILITY OF EITHER PARTY WHETHER
BASED ON 

  
 16 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 
CONTRACT LAW, TORTS OR ANY OTHER AREA OF LAW SHALL BE LIMITED TO THE AMOUNT PAID AND PAYABLE BY MAGENTA TO BACHEM UNDER THIS AGREEMENT IN THE TWELVE (12) MONTHS PRECEDING THE APPLICABLE CLAIM.
NOTWITHSTANDING THE FOREGOING, THESE LIMITATIONS SHALL NOT APPLY TO DAMAGES ARISING FROM A PARTY’S (I) INDEMNIFICATION OBLIGATIONS UNDER SECTION 11.1 OR SECTION 11.2 HEREOF, (II) GROSS NEGLIGENCE OR WILFUL MISCONDUCT, (III) BREACH
OF ITS OBLIGATIONS UNDER SECTION 9 OR (IV) INFRINGEMENT OR MISAPPROPRIATION OF THE OTHER PARTY’S INTELLECTUAL PROPERTY. 
 Section 12.
PUBLICITY AND PUBLICATIONS 
 Neither Magenta nor Bachem shall make any news release or other public statement, whether to the press or
otherwise, disclosing the existence of this Agreement, the terms thereof or of any amendment thereto, or any Project Plan without the prior written approval of the other Party, except as required by Applicable Laws. To the extent, if any, that a
Party concludes in good faith that it is required by Applicable Laws or regulations to file or register this Agreement or a notification thereof with any Governmental Authority, including the U.S. Securities and Exchange Commission, such Party may
do so, and the other Party shall cooperate in such filing or notification and shall execute all documents reasonably required in connection therewith. In such situation, the filing Party shall request confidential treatment of sensitive provisions
of the Agreement to the extent permitted by Applicable Laws. A Party may disclose this Agreement to a Third Party in connection with or in conjunction with a proposed merger, consolidation, sale of assets that include those related to this
Agreement, an assignment of this Agreement or loan financing, raising of capital, or sale of securities; provided, however, that the disclosing Party obtains an agreement for confidential treatment thereof with a limitation on use solely for
consideration of the relevant transaction. 
 Section 13. FORCE MAJEURE 

If either Party shall be delayed or hindered in or prevented from the performance of any act required hereunder by reason of strike, lockouts,
labor troubles, restrictive governmental or judicial orders or decrees, riots, insurrection, war, terrorist acts, acts of God, inclement weather or other reason or cause reasonably beyond such Party’s control (each a “Force
Majeure”), then performance of such act shall be excused for the period of such Force Majeure. The Party affected by the Force Majeure shall provide prompt written notice to the other Party of the commencement and termination of the Force
Majeure. Should a Force Majeure continue for more than two (2) months, the Party unaffected by the Force Majeure may terminate this Agreement upon prior written notice to the affected Party. If the Force Majeure equally affects the ability of
each Party to perform under this Agreement, then such termination shall only be by mutual written agreement. 
 Section 14. NOTICES 

All notices or other communications that are required or permitted by this Agreement shall be in writing and shall be delivered personally,
sent by fax (and promptly confirmed by overnight courier), sent by nationally recognized overnight courier, or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows: 

  
 17 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

			
	If to Magenta:	  	Magenta Therapeutics, Inc.
		  	 Attn: [***]
 50 Hampshire Street

8th Floor Cambridge, MA 02139

		  	 [***] 

		
	If to Bachem:	  	Bachem Americas, Inc.
		  	 Attn: [***]
 3132 Kashiwa Street, Torrance, CA
90505

		  	[***]

 All notices delivered pursuant to this Section 14 shall be considered delivered upon receipt by the intended recipient.

 Section 15. MISCELLANEOUS 
 15.1
Further Actions. The Parties shall duly execute and deliver, or cause to be duly executed and delivered, such further instruments, and to do and cause to be done such further acts that may be necessary to carry out the provisions and purposes
of this Agreement, notwithstanding any expiration or termination of this Agreement. 
 15.2 Amendments; Assignment. This Agreement,
including any Project Plans or other attachments, may not be altered, amended or modified except by a written document signed by both Parties. Bachem will not assign this Agreement without the prior written consent of Magenta, and any purported
assignment in contravention of this Section 15.2 shall be null and void; provided, however, that either Party may assign this Agreement in connection with (i) the sale, transfer or other disposition of its assets related to this
Agreement, (ii) a change in control of such Party, or (iii) the sale or transfer of substantially all of such Party’s outstanding stock. 

15.3 Subcontracting. Bachem shall not assign, subcontract or delegate any of its rights or obligations under this Agreement without the
express prior written authorization of Magenta, provided however, that Bachem may subcontract its rights and obligations hereunder to those subcontractors identified and agreed to by the Parties in the Quality Agreement. Bachem shall cause any such
authorized subcontractor to be subject by contract to the same restrictions, exceptions, obligations, reports, termination provisions and other provisions contained in this Agreement and any applicable Project Plan(s). Bachem shall remain primarily
obligated for all acts and omissions of any of its subcontractors as if Bachem had performed the subcontracted obligations itself, and shall guarantee the performance of the same. 

15.4 Successors; Assigns. This Agreement shall be binding upon and inure to the benefit of the Parties hereto and each of their
respective successors and permitted assigns. 
 15.5 Severability. All agreements and covenants contained herein are severable, and in
the event any of them shall be held to be invalid by any competent court, this Agreement shall be interpreted as if such invalid agreements or covenants were not contained herein. 

15.6 Entire Agreement. This Agreement, including the attached Project Plans, constitutes the entire agreement between the Parties
related to the subject matter hereof, and supersedes all prior communications, representations, or agreements, either verbal or written, between the Parties. Each Party confirms that it is not relying on any representations or warranties of the
other Party except as specifically set forth herein. 

  
 18 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 15.7 Independent Contractor. This Agreement shall not be deemed to create any
partnership, joint venture, or agency relationship between the Parties. Each Party shall act hereunder as an independent contractor, and its agents and employees shall have no right or authority under this Agreement to assume or create any
obligation on behalf of, or in the name of, the other Party. All persons employed by a Party shall be employees of such Party and not of the other Party, and all costs and obligations incurred by reason of any such employment shall be for the
account and expense of such Party. 
 15.8 Waiver. The waiver by either Party of any right hereunder shall not be deemed a waiver of
that same right in the future or a waiver of any other right hereunder. 
 15.9 Counterparts. This Agreement may be executed by
original or facsimile signature in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute the same instrument. 

15.10 Headings. The headings used in this Agreement are for convenience only and are not a part of this Agreement. 

15.11 Governing Law. This Agreement will be construed and interpreted and its performance governed by the laws of the State of New York,
without giving effect to its conflict of laws principles. The parties submit to the exclusive jurisdiction of the state and federal courts in New York for any suit, action or proceeding relating to this Agreement. 

15.12 Dispute Resolution. The parties shall attempt in good faith to resolve any dispute arising out of or relating to this Agreement
promptly by negotiations between executives who have authority to settle the controversy. Any party may give the other party written notice of any dispute not resolved in the normal course of business. Within [***] after delivery of said notice,
executives of both parties shall meet at a mutually acceptable time and place in the State of New York or as otherwise agreed and thereafter as often as they reasonably deem necessary to exchange relevant information and to resolve the dispute. Once
the executive of either party determines that additional meetings are not likely to resolve the dispute, each of the parties shall be entitled to terminate such meetings and the dispute shall be submitted to binding arbitration. The binding
arbitration shall be in accordance with the rules and procedures for commercial arbitration of the American Arbitration Association. Unless the parties to such dispute agree otherwise in writing, any such arbitration shall be conducted in New York
pursuant to New York law, without any consideration of conflict of law issues, and the results of such arbitration shall be final and binding on the parties and enforceable in any court of competent jurisdiction. Notwithstanding the foregoing, the
parties acknowledge and agree that each of them shall have the right to seek immediate injunctive and other equitable relief through the courts in the event of any material breach by the other party of any provision of this Agreement that would
cause the non-breaching party irreparable injury for which there would be no adequate remedy at law. Any such legal proceeding will be brought in the applicable state or federal court of the State of New York,
and the parties hereby consent to this exclusive jurisdiction for this purpose. 
 *     *    
*    *    * 

  
 19 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 IN WITNESS WHEREOF, each of the Parties hereto has caused this Master Development and
Manufacturing Agreement to be executed by its duly authorized representative as of the Effective Date. 
  

			
	Magenta Therapeutics, Inc.
		
	By:	 	 /s/ Christina Isacson

		 	Name: Christina Isacson
		 	Title: CBO
	
	Bachem Americas, Inc.
		
	By:	 	 /s/ Brian Gregs

		 	Name: Brian Gregs
		 	Title: COO
	
	Acknowledged by Bachem AG
		
	By:	 	 /s/ Beat Sax

		 	Name: Beat Sax
		 	Title: Site Manager
		
	By:	 	 /s/ Boris Corpateaux

		 	Name: Boris Corpateaux
		 	Title: VP BD & Sales

  
 20 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 APPENDIX A 

List of Existing Project Plans 
  

			
	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	

  
 21 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 [Form of Amendment to Appendix A] 

AMENDMENT TO APPENDIX A 

This Amendment to Appendix A is dated as of
[                        ], 20[_], and made pursuant to Section 3.1 of the Master Development and Manufacturing Agreement
(the “Master Agreement”), dated [                    ] [        ],
20[        ], between Magenta Therapeutics, Inc. and Bachem Americas, Inc. In consideration of the mutual promises contained in the Master Agreement and for other good and valuable consideration, the receipt
and adequacy of which each of the Parties does hereby acknowledge, the Parties hereby agree to amend Appendix A by adding the attached new Project Plan entitled
[                    ], which is designated as Project Plan A–[        ]. This Project Plan is effective
as of [                    ], 20[        ] and shall terminate on
[                    ], 20[        ], unless earlier terminated as permitted in the Master Agreement. 

Project Plan A–[        ] shall hereby be deemed incorporated into the Master Agreement
referenced above. 
  

			
	Magenta Therapeutics, Inc.
		
	By:	 	  

		 	Name:
		 	Title:
	
	Bachem Americas, Inc.
		
	By:	 	  

		 	Name:
		 	Title:

  
 22 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 APPENDIX B 

CXCR2 Ligand 
  

					
	[***]	  	[***]	  	Date Added
	[***]	  	 [***]
	  	Effective Date
	[***]	  	 [***]
	  	Effective Date
	[***]	  	 [***]
	  	Effective DateEX-10.11

 EXHIBIT 10.11 

CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[***]”. AN
UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 
 EXCLUSIVE RESEARCH, DEVELOPMENT 

OPTION AND LICENSE AGREEMENT 

This Agreement is entered into with effect as of the Effective Date (as defined below) 

by and between 
 Magenta Therapeutics, Inc.,

 with principal offices located at 50 Hampshire St., 8th floor, Cambridge, MA 02142, USA
(“MAGENTA”) 
 on the one hand 

and 
 Heidelberg Pharma Research GmbH 

with an office and place of business at Schriesheimer Strasse 101, D-68526 Ladenburg, Germany (“HDPR”)

 on the other hand. 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

TABLE OF CONTENTS 
  

									
	 	  	 	  	 	  	Page	 
	1.	  	Definitions	  	 	1	 
			
	2.	  	Research Plan; Governance	  	 	11	 
		  	2.1	  	Research Plan	  	 	11	 
		  	2.2	  	Amendments to Research Plan	  	 	11	 
		  	2.3	  	Duration	  	 	11	 
		  	2.4	  	Joint Steering Committee	  	 	12	 
			
	3.	  	Options and Licenses; Sublicensing	  	 	14	 
				
		  	3.1	  	Non-Exclusive Research License and Cross-License	  	 	14	 
		  	3.2	  	Option to Acquire an Exclusive Research License	  	 	14	 
		  	3.3	  	Exclusive Research Targets	  	 	14	 
		  	3.4	  	Option to Acquire Development Rights	  	 	16	 
		  	3.5	  	Exclusive Commercial License	  	 	16	 
		  	3.6	  	Grant-Back License	  	 	16	 
		  	3.7	  	Sublicensing	  	 	16	 
		  	3.8	  	Contractors	  	 	17	 
			
	4.	  	Diligence Requirements	  	 	17	 
			
	5.	  	Development	  	 	17	 
			
	6.	  	Supply of Compounds and Products; Technology Transfer	  	 	18	 
				
		  	6.1	  	Pre-Clinical Supply	  	 	18	 
		  	6.2	  	Clinical and Commercial Supply	  	 	22	 
		  	6.3	  	Quality Agreement	  	 	22	 
			
	7.	  	Regulatory	  	 	22	 
				
		  	7.1	  	Decision-Making	  	 	23	 
		  	7.2	  	Right of Reference	  	 	23	 
			
	8.	  	Commercialization	  	 	23	 
			
	9.	  	Payments	  	 	23	 
				
		  	9.1	  	Research and Manufacturing Payments	  	 	24	 
		  	9.2	  	Development Payments	  	 	25	 
		  	9.3	  	Sale Payments	  	 	26	 
		  	9.4	  	Royalty Payments	  	 	26	 
			
	10.	  	Accounting and Reporting	  	 	27	 
				
		  	10.1	  	Timing of Royalty Payments	  	 	27	 
		  	10.2	  	Payment Modalities	  	 	27	 
		  	10.3	  	Bank Account	  	 	27	 
		  	10.4	  	Late Payment	  	 	27	 
			
	11.	  	Taxes	  	 	27	 
				
		  	11.1	  	Responsibility	  	 	27	 
		  	11.2	  	Cooperation	  	 	27	 
			
	12.	  	Financial Auditing	  	 	28	 
				
		  	12.1	  	HDPR Right to Audit	  	 	28	 
		  	12.2	  	Overpayments and Underpayments	  	 	28	 

  
 i 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

									
	13.	  	Intellectual Property	  	 	28	 
				
		  	13.1	  	Background IP	  	 	28	 
		  	13.2	  	Ownership of Inventions	  	 	29	 
		  	13.3	  	German Statute on Employee’s Inventions	  	 	29	 
		  	13.4	  	Trademarks	  	 	29	 
		  	13.5	  	Right to Handle the Patents	  	 	29	 
		  	13.6	  	Infringement	  	 	30	 
			
	14.	  	Representations and Warranties	  	 	31	 
				
		  	14.1	  	Mutual Representations and Warranties	  	 	31	 
		  	14.2	  	Representations and Warranties of HDPR	  	 	31	 
		  	14.3	  	Covenants of HDPR	  	 	32	 
			
	15.	  	Indemnification	  	 	32	 
				
		  	15.1	  	Indemnification by MAGENTA	  	 	32	 
		  	15.2	  	Indemnification by HDPR	  	 	33	 
		  	15.3	  	Procedure	  	 	33	 
			
	16.	  	Limitation of Liability; Disclaimer	  	 	33	 
				
		  	16.1	  	Limitation of Liability	  	 	33	 
		  	16.2	  	Consequential Damages	  	 	33	 
		  	16.3	  	Disclaimer	  	 	34	 
			
	17.	  	Obligation Not to Disclose Confidential Information	  	 	34	 
				
		  	17.1	  	Non-Use and Non-Disclosure	  	 	34	 
		  	17.2	  	Permitted Disclosure	  	 	34	 
		  	17.3	  	Publications	  	 	35	 
			
	18.	  	Term and Termination	  	 	35	 
				
		  	18.1	  	Commencement and Term	  	 	35	 
		  	18.2	  	Termination	  	 	36	 
		  	18.3	  	Consequences of Termination and Expiration	  	 	38	 
		  	18.4	  	Rights in Bankruptcy	  	 	38	 
		  	18.5	  	Survival	  	 	38	 
			
	19.	  	Miscellaneous	  	 	38	 
				
		  	19.1	  	Governing Law; Place of Jurisdiction	  	 	38	 
		  	19.2	  	Disputes	  	 	38	 
		  	19.3	  	Assignment	  	 	39	 
		  	19.4	  	Independent Contractor	  	 	39	 
		  	19.5	  	Unenforceable Provisions and Severability	  	 	39	 
		  	19.6	  	Waiver	  	 	39	 
		  	19.7	  	Appendices	  	 	39	 
		  	19.8	  	Amendments	  	 	39	 
		  	19.9	  	Further Assurances	  	 	40	 
		  	19.10	  	Invoice Address	  	 	40	 
		  	19.11	  	Notice	  	 	40	 
		  	19.12	  	Rules of Construction	  	 	40	 
		  	19.13	  	Counterparts	  	 	40	 

  
 ii 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 RECITALS 

WHEREAS, HDPR controls proprietary technology and intellectual property relating to certain drug conjugation, payload and linker
technology, as well as protein-drug conjugates; and 
 WHEREAS, MAGENTA controls proprietary technology and intellectual property
relating to certain antibodies and antibody-like fragments; and 
 WHEREAS, MAGENTA and HDPR have performed mutually agreed research
activities under the Evaluation Agreement concluded as of October 18, 2016, and amended as of June 7, 2017 and as of October 26, 2017; and 

WHEREAS, MAGENTA wishes to have an exclusive option to research and develop for commercialization of Products (as defined below); and

 WHEREAS, HDPR is willing to grant to MAGENTA such exclusive option under its intellectual property rights to make, use, offer for
sale, sell and import and export such Products in the Territory for use in the Field (as such terms are respectively defined below), as contemplated herein; 

NOW, THEREFORE, in consideration of the mutual covenants and promises contained in this Agreement and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do hereby agree as follows: 

1. Definitions. As used in this Agreement, the following terms, whether used in the singular or plural, shall have the following meanings: 

1.1 Accounting Standards. The term “Accounting Standards” shall mean, with respect to a Party or its Sublicensees, US
generally accepted accounting principles (GAAP), International Financial Reporting Standards (IFRS) or such other similar national standards as such Party or its Sublicensee adopts, in each case, consistently applied. 

1.2 Affiliate. The term “Affiliate” shall mean any individual, corporation, association or other business entity that directly
or indirectly controls, is controlled by, or is under common control with the Party in question. As used in this definition of “Affiliate,” the term “control” shall mean the direct or indirect ownership of more than fifty percent
(>50%) of the stock having the right to vote for directors thereof or the ability to otherwise control the management of the corporation or other business entity whether through the ownership of voting securities, by contract, resolution,
regulation or otherwise. 
 1.3 Agreement. The term “Agreement” shall mean this document including any and all appendices
and amendments to it as may be added and/or amended from time to time in accordance with the provisions of this Agreement. 
 1.4
Agreement Term. The term “Agreement Term” shall mean the period of time commencing on the Effective Date and, unless this Agreement is terminated sooner as provided in Section 18.2, expiring on the date when no royalty or other
payment obligations under this Agreement are or will become due. 
 1.5 Amanitin. The term “Amanitin” shall mean [***]. 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 1.6 Amanitin Toxin Constructs. The term “Amanitin Toxin Constructs” shall
mean Amanitin, combined, where applicable, with a Linker(s). 
 1.7 Antibody. The term “Antibody” shall mean any antibody
and any fragment thereof, including any protein or any fragments thereof and any non-protein based scaffold. 

1.8 Applicable Law. The term “Applicable Law” shall mean all federal, state, local, national and supra-national laws,
statutes, rules and regulations, including any rules, regulations, regulatory guidelines or other requirements of Regulatory Authorities, major national securities exchanges or major securities listing organizations, that may be in effect from time
to time during the Agreement Term and applicable to a particular activity or country hereunder. 
 1.9 Blocked Target. The term
“Blocked Target” shall mean a Target that has been entered into the list maintained by the Trusted Person and which Target HDPR cannot make available to MAGENTA due to the fact that either: 

(a) [***]; or 
 (b) [***]. 

1.10 Business Day. The term “Business Day” shall mean a day other than a Saturday or Sunday on which banking institutions in
Frankfurt A.M., Germany or New York, New York are open for business. 
 1.11 Calendar Quarter. The term “Calendar Quarter”
shall mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31. 

1.12 Calendar Year. The term “Calendar Year” shall mean the period of time beginning on January 1 and ending
December 31, except for the first year which shall begin on the Effective Date and end on December 31. 
 1.13 [***]. 

1.14 Change of Control. The term “Change of Control” shall mean (a) the sale of all or substantially all the assets of
HDPR, (b) any merger, consolidation or acquisition of HDPR with, by or into another Person following which less than fifty percent (50%) of outstanding equity securities of the surviving entity or its ultimate parent entity of such transaction
are held by Persons who were the holders of HDPR equity securities immediately prior to such transaction or (c) any change in the ownership of fifty percent (50%) or more of the voting capital stock of HDPR, with respect to (a)-(c), in one
(1) or more related transactions. 
 1.15 Clinical Study. The term “Clinical Study” shall mean a Phase I, Phase II,
Phase III Study, as applicable. 

  
 2 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 1.16 Combination Products. The term “Combination Product” shall mean
(a) any single Product containing as active ingredients both a Compound and one or more other pharmaceutically active compounds or substances (whether co-formulated or
co-packaged) for a single invoice price, (b) any Product sold in combination with one (1) or more other products (such as devices) or services for a single invoice price or (c) any Product sold
where the sale of the Product is only available with the purchase of other products or services (such other pharmaceutically active compounds or substances, or such other products or services referred to in clauses (a) through (c) hereof, the
“Other Components”). For purposes of this definition, “active ingredient” shall mean any pharmaceutically active compound or substance that is recognized by the FDA as an active ingredient in accordance with 21 CFR 210.3(b)(7).

 1.17 Commercially Reasonable Efforts. The term “Commercially Reasonable Efforts” shall mean [***]. 

1.18 Compound. The term “Compound” shall mean an Antibody-drug conjugate directed at a Development Target, [***] (a) that is
Covered by one (1) or more of the Patents Rights included in the HDPR IP Rights, HDPR IP Improvements or Joint IP Rights or (b) that is discovered, identified or developed through the use or application of HDPR Know-How. 
 1.19 Confidential Information. The term “Confidential Information” shall mean
any and all non-public and proprietary information, data or Know-How, whether technical or non-technical, oral or written, that is disclosed by one Party or its
Affiliates (“Disclosing Party”) to the other Party or its Affiliates (“Receiving Party”) in connection with this Agreement. Notwithstanding the foregoing, Confidential Information shall not include any information, data or Know-How that verifiably: 
 (a) was generally available to the public at the time of disclosure hereunder
or becomes generally available to the public after disclosure hereunder, other than through fault (whether by action or inaction) or negligence of the Receiving Party or its Permitted Recipients as defined in
Section 17.2.4; 
 (b) can be evidenced by the Receiving Party’s written records to have been already known to
the Receiving Party prior to its receipt from the Disclosing Party; 
 (c) is obtained at any time lawfully by the Receiving Party from a
Third Party or, in case of MAGENTA, from a Sublicensee, under circumstances permitting its use or disclosure; 
 (d) is developed
independently by the Receiving Party as evidenced by written records other than through knowledge of Confidential Information; or 
 (e) is
approved in writing by the Disclosing Party for release by the Receiving Party. 
 The terms of this Agreement shall be considered
Confidential Information of both Parties. 
 1.20 Control. The term “Control” shall mean, when used in reference to a Party
and an item, intellectual property right or proprietary or trade secret information, the legal authority or right of such Party to grant the right to use such item or a license or sublicense of such intellectual property rights to the other Party,
or to otherwise disclose such proprietary or trade secret information to the other Party, in each case, without breaching the terms of any agreement with a Third Party pursuant to which such rights, item or information were acquired or generated or
misappropriating the proprietary or trade secret information or Know-How of a Third Party. 

  
 3 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 1.21 Cover. The term “Cover” shall mean (as a noun or as a verb including
conjugations and variations such as “Covered,” “Coverage” or “Covering”) that the developing, making, using, offering for sale, promoting, selling, exporting or importing of a given intermediate, compound, formulation
or product would infringe a Valid Claim in the absence of a license under or ownership of the Patent Rights to which such Valid Claim pertains. The determination of whether an intermediate, compound, formulation, process or product is Covered by a
particular Valid Claim shall be made on a country-by-country basis. 

1.22 Deductible Third Party Payments. The term “Deductible Third Party Payments” shall mean payments made by MAGENTA or its
Sublicensees to Third Parties under licenses or sublicenses of intellectual property that are reasonably necessary in order for MAGENTA or its Sublicensees to use, make, have made, manufacture, sell, have sold or import Amanitin Toxin Constructs.

 1.23 Development Target. The term “Development Target” shall mean an Exclusive Research Target for which MAGENTA has
exercised the Development Option Right according to Section 3.4. 
 1.24 dievini Group. The term “dievini Group” shall
mean the companies to which Hopp BioTech holding GmbH & Co. KG is an Affiliate. 
 1.25 Effective Date. The term
“Effective Date” shall mean March 1st, 2018. 
 1.26
EU. The term “EU” shall mean the European Economic Area and all its then-current member countries. 
 1.27 Exclusive
Research Target. The term “Exclusive Research Target” shall mean any Target for which MAGENTA has exercised the Exclusive Research Option Right according to Section 3.3, including the Initial Targets (as defined below). 

1.28 FDA. The term “FDA” shall mean the Food and Drug Administration of the United States of America and any successor
agency(ies) or authority having substantially the same function. 
 1.29 FDCA. The term “FDCA” shall mean the United States
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq., as amended from time to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions, and modifications
thereto). 
 1.30 Field. The term “Field” shall mean all therapeutic (including prophylactic) uses. 

1.31 First Commercial Sale. The term “First Commercial Sale” shall mean, on a Product-by-Product and country-by-country basis, the first invoiced sale of a Product to a Third Party end user for monetary
value by the MAGENTA Group following the receipt of any Regulatory Approval required for the sale of such Product in such country or, if no such Regulatory Approval is required, the date of the first invoiced sale of a Product to a Third Party end
user for monetary value by the MAGENTA Group in a country. For clarity, sales prior to receipt of Regulatory Approval for a Product in a country, such as so-called “treatment IND sales,” “named
patient sales” and “compassionate use sales,” will not be construed as a First Commercial Sale. 

  
 4 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 1.32 FTE. The term “FTE” shall mean the equivalent of the work of one
(1) employee full time for one (1) Calendar Year in conducting Research Activities. 
 1.33 Good Manufacturing Practices or
GMP. The term “Good Manufacturing Practices” or “GMP” means all Applicable Laws relating to manufacturing practices for products (including ingredients, testing, storage, handling, intermediates, bulk and finished products)
promulgated by the FDA and any other Regulatory Authority (including, without limitation, EU or member state level) having jurisdiction over the manufacturing practices for products, including, but not limited to, standards in the form of Applicable
Laws, guidelines, advisory opinions and compliance policy guides and current interpretations of the applicable authority or agency thereof (as applicable to pharmaceutical and biological products and ingredients), as the same may be updated,
supplemented or amended from time to time. 
 1.34 Handle. The term “Handle” shall mean preparing, filing, prosecuting
(including interference and opposition proceedings) and maintaining (including interferences, reissue, reexamination and opposition proceedings) of Patent Rights. 

1.35 HDPR IP Improvements. The term “HDPR IP Improvements” shall mean any Improvements that are Covered by the Patent Rights
included in the HDPR IP Rights or discovered, identified or developed through the use or application of the Know-How included in the HDPR IP Rights. 

1.36 HDPR Intellectual Property Rights or HDPR IP Rights. The term “HDPR Intellectual Property Rights” or “HDPR IP
Rights” shall mean the Patent Rights and Know-How that HDPR Controls on the Effective Date or during the Agreement Term that (a) are reasonably necessary or useful for the discovery, manufacture,
development or commercialization of Compounds or Products, (b) relate to [***] or (c) relate to [***]. 
 1.37 Improvements.
The term “Improvements” shall mean all Know-How and Patent Rights generated by the Parties in connection with the Research Activities and which relate to the research, development or
commercialization of Amanitin, an Amanitin Toxin Construct, a Linker, a Compound or a Product. 
 1.38
IND-Enabling Studies. The term “IND-Enabling Studies” shall mean GLP toxicology studies intended to support the filing of an application with Regulatory
Authorities to initiate a Phase I Study on a molecule directed toward a Development Target selected by MAGENTA in its sole discretion. 

1.39 Indication. The term “Indication” shall mean, with respect to a country, the labelled use of a Product for either
therapeutic (including prophylactic) treatment or for the prevention of a distinct illness, sickness, interruption, cessation or disorder of a particular bodily function, system, tissue type or organ, or sign or symptom of any such items or
conditions, regardless of the severity, frequency or route of any treatment, treatment regimen, dosage strength or patient class, for which Regulatory Approval has been obtained or is being sought in such country. 

  
 5 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 1.40 Initial Targets. The term “Initial Targets” shall mean the two Targets
set forth on Schedule 1.40, which have already undergone the clearance procedure set forth in Section 3.3.3 prior to the Effective Date of this Agreement. 

1.41 Initiation. The term “Initiation” shall mean (or as a verb including conjugations and variations) the date that the first
human is first dosed with a Product in a Clinical Study approved of by the applicable Regulatory Authority. 
 1.42 Insolvency Event.
The term “Insolvency Event” shall mean circumstances under which a Party (a) has a receiver or similar officer appointed over all or a material part of its assets or undertaking; (b) passes a resolution for winding-up (other than a winding-up for the purpose of, or in connection with, any solvent amalgamation or reconstruction) or a court makes an order to that effect or a court
makes an order for administration (or any equivalent order in any jurisdiction); (c) enters into any composition or arrangement with its creditors (other than relating to a solvent restructuring); (d) ceases to carry on business; or (e) is
unable to pay its debts as they become due in the ordinary course of business. 
 1.43
Know-How. The term “Know-How” shall mean all proprietary data, knowledge and information, including materials, samples, techniques, practices, methods,
procedures, processes, chemical manufacturing data, toxicological data, pharmacological data, preclinical data, assays, platforms, formulations, specifications, quality control testing data and documentation thereof. 

1.44 Linker. The term “Linker” shall mean [***]. 

1.45 MAGENTA Group. The term “MAGENTA Group” shall mean MAGENTA and its Sublicensees. 

1.46 MAGENTA Intellectual Property Rights or MAGENTA IP Rights. The term “MAGENTA Intellectual Property Rights” or
“MAGENTA IP Rights” shall mean all Patent Rights and Know-How Controlled by MAGENTA that are reasonably necessary or useful for HDPR to conduct its activities under the Research Plan. 

1.47 Net Sales. The term “Net Sales” shall mean, in the case of sales by or for the benefit of MAGENTA Group (the
“Seller”) to independent, unrelated Third Party end users in bona fide arm’s length transactions, the aggregate gross amount invoiced by Seller with respect to the Product, less the following deductions, in each case to the extent
actually allowed and taken and not otherwise recovered by or reimbursed to Seller in connection with such Product: 
 (a) [***]; 

(b) [***]; 
 (c) [***]; 

(d) [***]; 
 (e) [***]; 

(f) [***]; and 

  
 6 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 (g) [***]. 

Notwithstanding anything to the contrary, [***]. 

In the case of any Combination Product sold in a country in the Territory, Net Sales for such Combination Product in such country shall be
calculated by [***]. In the event the Parties are unable to agree on such value, then such disagreement shall be resolved in accordance with the dispute resolution procedures set forth in Section 19.2. 

1.48 Non-Exclusive Research Target. The term
“Non-Exclusive Research Target” shall mean all Targets on which the Parties will conduct Technology Research Activities. 

1.49 Party. The term “Party” shall mean HDPR or MAGENTA, as the case may be, and “Parties” shall mean HDPR and
MAGENTA, collectively. 
 1.50 Patent Rights. The term “Patent Rights” shall mean (a) issued patents and pending patent
applications, including inventor’s certificates, applications for inventor’s certificates, statutory invention registrations, applications for statutory invention registrations, utility models and any foreign counterparts thereof,
(b) any and all provisionals, non-provisionals, substitutions, continuations, continuations-in-part or divisionals or the patents or patent applications listed in
subsection (a) or any other patent application claiming priority directly or indirectly to (i) any of the patents or patent applications in subsection (a) or (ii) any patent or patent application from which the patents or patent
applications in subsection (a) claim direct or indirect priority, (c) all patents issuing on any of the foregoing in (a)-(b), (d) all foreign and other counterparts of any of the foregoing in (a)-(c), whether pending or issued, including
any patent applications filed under the Patent Cooperation Treaty and (e) all other continuing applications, extensions or restorations by existing or future extension or restoration mechanisms, including patent term extension, supplementary
protection certificates (or the equivalent), renewals, letters patent, reissues, reexaminations, extensions, confirmations, registrations and patents of addition on any of the foregoing in subsections (a)-(d). 

1.51 Person. The term “Person” shall mean any individual, firm, corporation, partnership, limited liability company, trust,
business trust, joint venture, governmental authority, association or other entity. 
 1.52 Phase I Study. The term “Phase I
Study” shall mean a human clinical trial in any country that would satisfy the requirements of 21 C.F.R. § 312.21(a) (FDCA), as amended from time to time, and the foreign equivalents thereof. 

1.53 Phase II Study. The term “Phase II Study” shall mean a human clinical trial for which the primary endpoints include a
determination of dose ranges and/or a preliminary determination of efficacy in patients being studied as described in 21 C.F.R. § 312.21(b) FDCA, as amended from time to time, and the foreign equivalents thereof. 

1.54 Phase III Study. The term “Phase III Study” shall mean a human clinical trial that is prospectively designed to
demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain Regulatory Approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R.
§ 312.21(c) FDCA, as amended from time to time, and the foreign equivalents thereof. 

  
 7 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 1.55 Product. The term “Product” shall mean all formulations of a product
containing a Compound, including the use of a Compound by itself. 
 1.56 Regulatory Approval. The term “Regulatory
Approval” shall mean, with respect to a country in the Territory, any approval (including pricing and reimbursement approvals, if applicable), license, registration or authorization of any Regulatory Authority necessary for the manufacture and
sale of a Product in such country. 
 1.57 Regulatory Authority. The term “Regulatory Authority” shall mean any national,
supranational (e.g., the European Commission, the Council of the European Union, the European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity including the FDA, in
each country involved in the granting of Regulatory Approval for the Product. 
 1.58 Research Plan. The term “Research
Plan” shall mean the plan of research attached as Appendix 1 and outlining the work, including Research Activities, to be performed by the Parties, and the additional information described in Section 2.1, as such plan may be updated from
time to time pursuant to the terms of this Agreement. 
 1.59 Royalty Term. The term “Royalty Term” shall mean, with respect
to a Product for a given country, the period of time commencing on the date of First Commercial Sale of such Product in such country and ending on the later of the date that is (a) ten (10) years after the date of the First Commercial Sale of such
Product in such country if no Valid Claim of the Patent Rights included in the HDPR IP Rights or Joint IP Rights in such country Covers the use, import, offering for sale or sale of the Product or (b) the expiration of the last to expire Valid
Claim of the Patent Rights included in the HDPR IP Rights or Joint IP Rights Covering the use, import, offering for sale or sale of such Product in such country. 

1.60 Target. The term “Target” means the molecular target (that is determined by specifying the amino acid sequence and/or the
gene sequence of the corresponding antigen, including all fragments, mutations, and splice variants thereof and unique UniProtKB/Swiss Prat accession number) of a pharmacologically active drug compound. 

1.61 Target Research Activities. The term “Target Research Activities” shall mean the activities undertaken by the Parties
pursuant to the Research Plan with respect to identifying Compounds and developing Products directed towards the Exclusive Research Targets. 

1.62 Target Research Term. The term “Target Research Term” shall mean, on an Exclusive Research
Target-by-Exclusive Research Target basis, the period of time commencing on the date MAGENTA exercises its Exclusive Research Option Right and the Parties mutually agree
on an amendment to the Research Plan with respect to an Exclusive Research Target and continuing until the earlier of (a) [***] thereafter or (b) [***]; provided that, the Target Research Term for the Initial Targets shall end upon the earlier of
(i) the [***] or (ii) upon [***]. 
 1.63 Technology Research Activities. The term “Technology Research
Activities” shall mean the activities undertaken by the Parties pursuant to the Research Plan with respect to identifying Compounds and developing Products directed towards the Non-Exclusive Research
Targets. 
 1.64 Territory. The term “Territory” shall mean all countries of the world. 

  
 8 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 1.65 Third Party. The term “Third Party” shall mean a Person or entity other
than (a) HDPR or any of its Affiliates or (b) MAGENTA or its Affiliates or its Sublicensees. 
 1.66 Transfer. The term
“Transfer” shall mean (as a noun or as a verb including conjugations and variations such as “Transferred” or “Transferring”) that all necessary or useful relevant Know-How,
whether or not documented, is made available to MAGENTA or its designee in a way that enables MAGENTA to implement such Know-How in its manufacturing and supply processes. For the avoidance of doubt, such
Transfer is without prejudice to the ownership of HDPR IP Rights as set forth in Article 13. 
 1.67 Transplantation Indication
Product. The term “Transplantation Indication Product” shall mean a Product approved for use for Indications that include hematopoietic stem cell transplant and that is not a Tumor Indication Product. 

1.68 Tumor Indication Product. The term “Tumor Indication Product” shall mean a Product for therapeutic treatment of a
distinct oncological illness, sickness, interruption, cessation or disorder of a particular bodily function, system, tissue type or organ, or sign or symptom of any such items or conditions, such as breast cancer, prostate cancer, colon cancer,
gastric cancer, lung cancer, regardless of the severity, frequency or route of any treatment, treatment regimen, dosage strength or patient class, for which Regulatory Approval has been obtained or is being sought. 

1.69 Trusted Person. The term “Trusted Person” shall mean [***]. 

1.70 US. The term “US” shall mean the United States of America and its territories and possessions. 

1.71 USD. The term “USD” shall mean US Dollars. 

1.72 Valid Claim. The term “Valid Claim” shall mean, as applicable, a claim in any (a) unexpired and issued Patent Rights
that have not been disclaimed, revoked or held invalid by a final non-appealable decision of a court of competent jurisdiction or government agency or (b) a pending patent application that has not been
finally abandoned, finally rejected or expired (after exhaustion of all appeals); provided, however, that if a claim of a pending patent application shall not have been issued within [***] after the earliest filing date from which such claim takes
priority, such claim shall not constitute a Valid Claim for the purposes of this Agreement unless and until a patent issues with such claim. 

1.73 Additional Definitions. Each of the following definitions is set forth in the Section of this Agreement indicated below: 

 

			
	 Definition
	  	
(Sub-) Section

	 ADC Batch
	  	6.1.1(c)
	 Bankruptcy Code
	  	18.4.1
	 Breaching Party
	  	18.2.1
	 Buy-Out Option
	  	9.4.4
	 Buy-Out Option Exercise Notice
	  	9.4.4
	 Buy-Out Option Exercise Fee
	  	9.4.4
	 Competitive Infringement
	  	13.6.2
	 Conjugation
	  	6.1.1(c)
	 Contractor
	  	3.8

  
 9 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

			
	 Definition
	  	(Sub-) Section
	Development Milestone	  	9.2.3(a)
	Development Option Fee	  	9.2.1
	Development Option Right	  	3.4
	Disclosing Party	  	1.19
	Exclusive Research Option Right	  	3.2
	Grant-Back License	  	3.6
	GMP Full Manufacturing Process	  	6.2.1(c)
	GMP Full Manufacturing Technology Transfer	  	6.2.1(c)
	GMP Full Manufacturing Technology Transfer Agreement or GFMTTA	  	6.2.1(c)
	HDPR	  	Cover Page
	Indemnified Party	  	15.3
	Indemnifying Party	  	15.3
	Intellectual Property	  	18.4.1
	Joint IP Rights	  	13.2.3
	Joint Steering Committee	  	2.4.1
	MAGENTA	  	Cover Page
	MAGENTA IP Improvements	  	13.2.1
	Non-Breaching Party	  	18.2.1
	Non-GMP Full Manufacturing Process	  	6.1.2(b)
	Non-GMP Full Manufacturing Technology Transfer	  	6.1.2(b)
	Non-GMP Partial Manufacturing Process	  	6.1,1(c)(ii)
	Non-GMP Partial Manufacturing Technology Transfer	  	6.1.1 (c)(ii)
	Order	  	6.1.1(c)(i)
	Other Components	  	1.16
	Peremptory Notice Period	  	18.2.1
	Permitted Recipients	  	17.2.4
	Product Marks	  	13.4
	Proposed Target	  	3.3.3
	Publishing Notice	  	17.3(b)
	Publishing Party	  	17.3(b)
	Receiving Party	  	1.19
	Reference License	  	7.2
	Reference Purpose	  	7.2
	Research Target Fee	  	9.1.2
	Research Target Extension Fee	  	9.1.2
	Royalty Rates	  	9.4.1
	Sales Milestone	  	9.3.1
	Seller	  	1.47
	Sublicensee	  	3.7
	Technology Fee	  	9.1.1
	Technology Research Term	  	2.3.1
	Trusted Person	  	1.69

  
 10 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 2. Research Plan; Governance. 

2.1 Research Plan. As more fully set forth herein, MAGENTA and HDPR shall conduct mutually agreed to Target Research Activities and
Technology Research Activities (together referred to as the “Research Activities”) pursuant to the Research Plan. The Research Plan will set forth (a) the Technology Research Activities and Target Research Activities to be conducted
by the Parties, (b) the activities and specific objectives of the Parties in conducting such activities and (c) the anticipated budget necessary for conducting such activities. 

2.2 Amendments to Research Plan. 

2.2.1 Required Amendments. Within [***] of MAGENTA exercising its Exclusive Research Option Rights with respect to an Exclusive Research
Target, the JSC will update the Research Plan to set forth the Target Research Activities to be conducted by the Parties in connection with such Exclusive Research Target, including the objectives, FTEs, other resources and anticipated budget
required for such activities, including, as further detailed in Section 6.1.1, with respect to HDPR’s supply obligations. 

2.2.2 Other Amendments. Either Party may, through its representatives on the JSC, propose amendments to the Research Plan at any time,
including with respect to the quantity or specifications of non-GMP quality Antibody-drug conjugate material, Amanitin Toxin Constructs and Amanitin required to be manufactured and supplied by HDPR during the
initial twelve (12) month period following the Effective Date and during any additional periods agreed to by the JSC pursuant to Section 2.4.3(d). 

2.3 Duration. 
 2.3.1
Technology Research Activities. The Technology Research Activities shall commence on the Effective Date and will continue for a period of [***] thereafter (the “Technology Research Term”). MAGENTA will pay to HDPR the fee for
the initial [***] period in accordance with Section 9.1.1 The Technology Research Term may be extended by MAGENTA, in its sole discretion, for additional [***] periods, up to a maximum total of [***] such extensions. If
MAGENTA intends to extend the Technology Research Term for an additional [***], MAGENTA shall notify HDPR at least [***] prior to the expiration of the Technology Research Term (or the then-current [***] extension period) and pay to HDPR the fee for
such extension in accordance with Section 9.1.1. 
 2.3.2 Target Research Activities. Target Research
Activities shall commence, on an Exclusive Research Target-by-Exclusive Research Target basis, upon MAGENTAIs exercise of its Exclusive Research Option Right and the
Parties mutually agreeing on an amendment to the Research Plan with respect to a Target (at which time, such Target shall be an Exclusive Research Target) and shall continue until the end of the Target Research Term for such Exclusive Research
Target. 

  
 11 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 2.4 Joint Steering Committee. 

2.4.1 Composition. Promptly after the Effective Date, the Parties will establish a joint steering committee (“Joint Steering
Committee” or “JSC”), which will oversee the Research Activities and serve as a forum for coordination and communication between the Parties. The JSC will consist of [***], who each will have the appropriate expertise in
product discovery, pre-clinical development, clinical development, regulatory and commercial matters to make decisions on behalf of the Parties with respect to the matters falling within the jurisdiction of
the JSC. MAGENTA will select from its representatives the chairperson for the JSC. Each Party may change to its representatives on the JSC by written notice to the other Party, including, with respect to MAGENTA, the representative who will serve as
chairperson. The JSC will have the right to adopt such standing rules as will be necessary for its work, to the extent that such rules are not inconsistent with this Agreement. From time to time, the JSC may establish one (1) or more sub-committees comprised of an equal number of representatives of each Party on an “as-needed” basis to oversee particular projects or activities (for example, joint
project team, joint finance group or joint intellectual property group), which sub-committees shall (a) be subject to the oversight, review and approval of, and will report to, the JSC, (b) make
decisions by consensus, with each Party’s representatives on such sub-committee collectively having one (1) vote and (c) meet as frequently as prescribed by the JSC. If a sub-committee is unable to reach consensus with respect to an issue, then such issue shall be referred to the JSC for consideration and resolution. In no event will the authority of a
sub-committee exceed that specified by the JSC for such sub-committee. All members of the JSC (and any sub-committee) shall be
subject to written confidentiality obligations commensurate in scope to the provisions of Section 16. 
 2.4.2
Meetings, Procedural Rules and Minutes. The JSC shall meet in person, by teleconference or by videoconference at least quarterly, or with such other frequency as the Parties may mutually agree. The location of
in-person JSC meetings will alternate between locations designated by HDPR and locations designated by MAGENTA. The chairperson of the JSC will be responsible for calling meetings on no less than fifteen
(15) Business Days’ notice, unless exigent circumstances require shorter notice. Each Party will make all proposals for agenda items and will provide all appropriate information with respect to such proposed items at least ten
(10) Business Days in advance of the applicable meeting. Meetings of the JSC will be effective only if at least one (1) representative from each Party is present or participating in such meeting (at which time, a quorum will exist), and
each Party shall use reasonable efforts to ensure that at least one (1) of its representatives attends each such meeting. The JSC will take action by consensus of the representatives present at a meeting at which a quorum exists, with each
Party having a single vote irrespective of the number of representatives of such Party in attendance, and each Party will use good faith efforts to reach consensus on all issues presented to the JSC. With the prior consent of the other Party (not to
be unreasonably withheld or delayed), other employees or consultants of either Party who are not representatives of such Party on the JSC (including a Party’s Alliance Manager) may attend meetings of the JSC; provided that such attendees
(a) will not vote in the decision-making process of the JSC and (b) are bound by obligations of confidentiality and non-disclosure. The JSC will designate an individual to prepare and circulate for
review and approval of the Parties minutes of each meeting ten (10) Business Days after the meeting. The Parties will agree on the minutes of each meeting promptly, but in no event later than the next meeting of the JSC. Each Party will be
responsible for all travel and related costs and expenses for its members and other representatives to attend meetings of, and otherwise participate on, the JSC or sub-committees. Each Party may replace its
JSC representatives at any time by notice in writing to the other Party. The first meeting of the JSC shall be held within [***] after the Effective Date. 

2.4.3 Responsibilities. The JSC shall be responsible for the following: 

(a) overseeing the conduct of the Research Plan and Research Activities; 

(b) providing a forum for consensual decision-making with respect to the Research Plan; 

  
 12 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 (c) preparing, updating or approving, as applicable, the Research Plan for each Exclusive
Research Target pursuant to Section 2.2; 
 (d) preparing, updating or approving, as applicable, the Research Plan
to specify the quantity and specifications of non-GMP quality Antibody-drug conjugate material, Amanitin Toxin Constructs and Amanitin to be manufactured and supplied by HDPR pursuant to
Section 6.1 during the initial [***] period following the Effective Date and after such period; 
 (e) monitoring
the Parties’ compliance with their respective obligations under the Research Plan; 
 (f) reviewing and circulating to the Parties any
data, reports or other information submitted to the JSC by a Party that arises from such Party’s Research Activities conducted pursuant to the Research Plan; 

(g) pursuant to Section 2.2, reviewing and approving any proposed amendments to the Research Plan proposed by either
Party, and evaluating any substantive departures by either Party from the Research Plan and the proposed resolution with respect to such departures; 

(h) agreeing to [***]; 
 (i)
periodically reviewing and revising the specifications to which HDPR (or its Third Party designee) will manufacture and supply of Antibody-drug conjugate material, Amanitin Toxin Constructs and Amanitin pursuant to
Section 6.1.4; 
 (j) pursuant to Section 6.2, determining the Party, Third Party or
Magenta Designee responsible for the manufacture and supply of GMP-quality Amanitin Toxin Constructs and Amanitin for GLP toxicology studies and all clinical development and commercial uses, and, if applicable
pursuant to Section 6.2.1(a), determining the proposed terms and conditions by which HDPR will supply MAGENTA; 

(k) providing a forum for the Parties to update each other on any Improvements; and 

(l) making such other decisions as may be delegated to the JSC pursuant to the terms of this Agreement or by the mutual written Agreement of
the Parties after the Effective Date. 
 2.4.4 Decision-Making; Limitations on Authority. If the JSC is unable to reach consensus on
an issue presented at any JSC meeting or within a period of [***] thereafter, including with respect to any amendment to the Research Plan, then MAGENTA will have final decision-making authority with respect thereto; provided that MAGENTA may
not, without the approval of the HDPR representatives on the JSC or HDPR’s written consent, amend the Research Plan to impose on HDPR any new obligation to perform research activities if such new obligations (a) would require capabilities
beyond the reasonable capabilities of HDPR that could not reasonably be subcontracted by HDPR to a Third Party or (b) would reasonably be expected to cause HDPR to incur additional FTE costs and direct out-of-pocket costs beyond those contemplated by this Agreement, unless MAGENTA has agreed in writing to reimburse HDPR for all such reasonable and documented additional costs that may be incurred by HDPR in
performing such new obligation. 

  
 13 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 2.4.5 Alliance Managers. Each Party will appoint one (1) or more employee(s) of
such Party who will oversee contact between the Parties for all matters between meetings of each JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date (each, an “Alliance
Manager”). Each Party may replace its Alliance Manager at any time by notice in writing to the other Party. 
 3. Options and Licenses;
Sublicensing. 
 3.1 Non-Exclusive Research License and Cross-License. 

3.1.1 HDPR Grant. HDPR hereby grants to MAGENTA during the Technology Research Term a worldwide,
non-exclusive and fee-bearing, right and license under the HDPR IP Rights and HDPR IP Improvements solely to enable MAGENTA to perform, or have performed on its behalf,
Technology Research Activities on Non-Exclusive Research Targets, as more fully set forth in the Research Plan. Subject to Section 3.8, MAGENTA may sublicense the rights granted to it
in this Section 3.1.1 to Contractors engaged by MAGENTA to perform Technology Research Activities on its behalf. In connection with the grant of such right and license for the Technology Research Term, MAGENTA will pay HDPR
the Technology Fees as more fully set forth in Section 9.1.1. 
 3.1.2 Confidentiality. The identity of any Non-Exclusive Research Target on which MAGENTA (or its permitted Contractors) is conducting Technology Research Activities will not be disclosed to HDPR until MAGENTA chooses to exercise its Exclusive Research
Option Right with respect to such Non-Exclusive Research Target in accordance with Section 3.3. 

3.1.3 MAGENTA Grant. MAGENTA hereby grants to HDPR during the Technology Research Term a worldwide and
non-exclusive right and license under the MAGENTA IP Rights and MAGENTA IP Improvements, without the right to transfer, assign or sublicense to a Third Party in any respects, solely to enable HDPR to perform
those Technology Research Activities applicable to HDPR, as set forth in the Research Plan. 
 3.2 Option to Acquire an Exclusive Research
License. During the Technology Research Term, HDPR hereby grants to MAGENTA the option to acquire an exclusive license under the HDPR IP Rights and HDPR IP Improvements with respect to [***] Targets (the “Exclusive Research Option
Right”), which exclusive licenses would by granted on a Target-by-Target basis and enable MAGENTA to conduct Target Research Activities with respect to such Targets as more fully set forth in
Section 3.3.4. 
 3.3 Exclusive Research Targets. 

3.3.1 Initial Targets. The Exclusive Research Option Right is deemed exercised by MAGENTA for the Initial Targets as of the Effective
Date. In connection with MAGENTA’s exercise of its Exclusive Research Option Right for the Initial Targets, MAGENTA will pay HDPR the Research Target Fees as more fully set forth in Section 9.1.2. 

3.3.2 Additional Targets. In connection with MAGENTA exercising its Exclusive Research Option Right for Targets other than the Initial
Targets, MAGENTA shall follow the notification and selection procedures set forth in Section 3.3.3 with respect to such Targets (such Targets, once MAGENTA has exercised its Exclusive Research Option Right with respect
thereto, together with the Initial Targets, the “Exclusive Research Targets”). In connection with MAGENTA’s exercise of its Exclusive Research Option Right for such other Targets, MAGENTA will pay HDPR the Research Target Fees
as more fully set forth in Section 9.1.2. 

  
 14 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 3.3.3 Selection of Exclusive Research Targets. HDPR will provide the Trusted Person
with an up-to-date written list of all Blocked Targets. Before selecting a Target as an Exclusive Research Target, MAGENTA shall provide a confidential written notice to
the Trusted Person proposing a Target (each, a “Proposed Target”) to be designated as an Exclusive Research Target. The Trusted Person, after comparing the Proposed Target to the list of Blocked Targets, shall simultaneously notify
MAGENTA and HDPR, in writing, whether the Proposed Target is a Blocked Target. If the Proposed Target is a Blocked Target, then (a) the Trusted Person shall not disclose the identity of the Proposed Target to HDPR, including in its written
notice and (b) MAGENTA will not be deemed to have used one (1) of its Exclusive Research Option Rights with respect to such Target. If the Proposed Target is not a Blocked Target, then (i) the Trusted Person will disclose the identity
of the Proposed Target in its written notice to the Parties, (ii) MAGENTA will be deemed to have used one (1) of its Exclusive Research Option Rights with respect to such Proposed Target, (iii) MAGENTA will pay the Research Target Fee
as set forth in Section 9.1.2(a) and (iv) from and after the date of the Trusted Person’s written notice, such Proposed Target shall constitute an Exclusive Research Target. 

3.3.4 Exclusive Research License. Upon (a) the Effective Date, with respect to the Initial Targets and (b) receipt of the
written notice from the Trusted Person pursuant to Section 3.3.3 that a Proposed Target is not a Blocked Target, with respect to each ((a)-(b)), HDPR hereby grants to MAGENTA, on an Exclusive Research Target-by-Exclusive Research Target basis, during the Target Research Term, an exclusive, worldwide, fee-bearing right and license
under the HDPR IP Rights and HDPR IP Improvements to enable MAGENTA to perform, or have performed on its behalf, Target Research Activities on such Exclusive Research Target, as more fully set forth in the Research Plan. In connection with the grant
of such right and license for the Target Research Term, MAGENTA will pay HDPR the Research Target Fees as more fully set forth in Section 9.1.2. For clarity, this exclusive license grant expressly includes the right for
MAGENTA (and its Contractors) to conduct GLP toxicology studies. Subject to Section 3.8, MAGENTA may sublicense the rights granted to it in this Section 3.3.4 to Contractors engaged by MAGENTA to
perform Target Research Activities on its or their behalf. Notwithstanding the foregoing, HDPR will retain the right to conduct, or have conducted on its behalf, on its own or together with Third Parties, internal and
non-clinical research with respect to Exclusive Research Targets, as long as (a) such activities are not directed at research or production of GMP material and do not include GLP toxicity studies,
(b) HDPR Controls any and all intellectual property, including Patent Rights and Know-How, arising in connection with such research that would constitute HDPR IP Rights but for the lack of such Control
and (c) HDPR shall not, either directly or indirectly through Affiliates or Third Parties, publish or otherwise disclose any data, information, inventions (whether or not patentable) or intellectual property rights arising in connection with
such research; provided that, subject to MAGENTA’s prior written consent, HDPR may disclose such data, information, inventions (whether or not patentable) or intellectual property rights to bona fide potential investors that are bound by
confidentiality obligations at least as restrictive as those set forth in this Agreement. 
 3.3.5 Termination. If MAGENTA terminates
its exclusive license for an Exclusive Research Target pursuant to Section 18.2.1 or Section 18.2.3, then, from and after the effective date of such termination, such Exclusive Research Target
shall be deemed a Non-Exclusive Research Target for which MAGENTA maintains a non-exclusive license pursuant to Section 3.1.1 [***]. 

  
 15 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 3.4 Option to Acquire Development Rights. On an Exclusive Research Target-by-Exclusive Research Target basis, during the Target Research Term for an Exclusive Research Target, HDPR hereby grants to MAGENTA the option to obtain an exclusive
development and commercial license with respect to such Exclusive Research Target (the “Development Option Right”). MAGENTA may exercise its Development Option Right for any Exclusive Research Target by notifying HDPR in writing of
the identity of the Exclusive Research Target for which MAGENTA wishes to exercise its Development Option Right and paying HDPR the Development Option Fee as more fully set forth in Section 9.2.1. Upon HDPR’s receipt
of such notice, such Exclusive Research Target shall be a Development Target for purposes of this Agreement. 
 3.5 Exclusive Commercial
License. Upon MAGENTA’s exercise of its Development Option Right with respect to an Exclusive Research Target pursuant to Section 3.4 and payment of the Development Option Fee as set forth in
Section 9.2.1, at which time such Exclusive Research Target shall become a Development Target, HDPR hereby grants to MAGENTA, with respect to such Development Target, an exclusive, worldwide, royalty-bearing, freely
transferable and sublicensable (through multiple tiers) right and license under the HDPR IP Rights and HDPR IP Improvements to develop, have developed, register, have registered, use, have used, make, have made, import, have imported, export, have
exported, market, have marketed, distribute, have distributed, sell and have sold Products in the Field in the Territory directed toward such Development Target. Notwithstanding the foregoing, HDPR will retain the right to conduct, or have conducted
on its behalf, on its own or together with Third Parties, internal and non-clinical research with respect to Development Targets, as long as (a) such activities are not directed at research or production
of GMP material and do not include GLP toxicity studies, (b) HDPR Controls any and all intellectual property, including Patent Rights and Know-How, arising in connection with such research that would
constitute HDPR IP Rights but for the lack of such Control and (c) HDPR shall not, either directly or indirectly through Affiliates or Third Parties, publish or otherwise disclose any data, information, inventions (whether or not patentable) or
intellectual property rights arising in connection with such research; provided that, subject to MAGENTA’s prior written consent, HDPR may disclose such data, information, inventions (whether or not patentable) or intellectual property
rights to bona fide potential investors that are bound by confidentiality obligations at least as restrictive as those set forth in this Agreement. 

3.6 Grant-Back License. MAGENTA hereby grants to HDPR a worldwide, royalty-free and
non-exclusive license under its interest in Joint IP Rights, for non-clinical research purposes only, with the right to sublicense Third Parties to do the same,
(“Grant-Back License”). For the avoidance of doubt, HDPR is prohibited from using the rights or licenses granted under the Grant-Back License for the clinical development or commercialization of compounds or products. 

3.7 Sublicensing. MAGENTA will have the right to grant sublicenses, through multiple tiers, under the rights granted to it in
Sections 3.5 and 72, to its Affiliates and to Third Parties (each, a “Sublicensee”) (for clarity, each Third Party to which a sublicense is granted according to this Section 3.7 ceases to be a
Third Party and becomes a Sublicensee); provided that: 
 3.7.1 any such sublicenses will be granted pursuant to a written agreement
that is consistent with the terms and conditions of this Agreement; 
 3.7.2 MAGENTA shall remain liable for any breach by a Sublicensee
would constitute a breach of this Agreement; and 

  
 16 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 3.7.3 any such sublicenses of the rights granted to MAGENTA under
Section 3.5 will terminate automatically upon termination of this Agreement with respect to the sublicensed rights; provided that such sublicense shall not terminate if, as of the effective date of such
termination, the Sublicensee is not in material breach of its obligations to MAGENTA under its sublicense agreement, the Sublicensee was previously granted an exclusive sublicense to develop or commercialize one (1) or more Products and, within
[***] of such termination, the Sublicensee agrees in writing to be bound directly to HDPR under a license agreement substantially similar to this Agreement with respect to the rights sublicensed hereunder, substituting such Sublicensee for MAGENTA;
and provided, further, that (a) such license agreement shall not prejudice any remedy either Party may have against the other in connection with such termination of this Agreement (in whole or in part); (b) the scope of the
rights granted to the Sublicensee under such license agreement (with respect to licensed activities, Products and territory) shall be equal to the scope of the rights that had been sublicensed by MAGENTA to the Sublicensee pursuant to the sublicense
agreement; (c) MAGENTA shall no longer be obligated under this Agreement to pay amounts set forth in this Agreement, to the extent such amounts are payable based on the activities of such Sublicensee from and after the effective date of such
termination; (d) such license agreement shall obligate the Sublicensee to pay directly to HDPR amounts corresponding to those set forth in Section 9 which are payable based on the activities of such Sublicensee from
and after the effective date of such termination; and (e) such license agreement shall not modify the rights and obligations of the Parties following any termination of this Agreement, in whole or in part. 

3.8 Contractors. MAGENTA will have the right to subcontract any of its activities under this Agreement to a Third Party or to a
Sublicensee, including a contractor or contract research organization (each such Third Party or Sublicensee, as applicable, a “Contractor”); provided that it obtains a written undertaking from the Contractor that it
will be subject to the confidentiality provisions of Section 17 and that MAGENTA and its Affiliates, as applicable, shall remain liable for any breach by a Contractor, in particular for those that would constitute a
material breach of this Agreement. 
 4. Diligence Requirements. 

4.1.1 Obligation. MAGENTA and HDPR shall use Commercially Reasonable Efforts to perform all Research Activities assigned to it under the
Research Plan. If MAGENTA exercises its Development Option Right with respect to an Exclusive Research Target (at which time, such Exclusive Research Target will be a Development Target), then MAGENTA agrees to use Commercially Reasonable Efforts to
pursue development and commercialization of a Product directed toward the applicable Development Target in the Field in the Territory. 

4.1.2 Performance Through Sublicensees and Contractors. Where provisions of this Agreement provide that MAGENTA is responsible for a
matter or activity, including Research Activities or the use of Commercially Reasonable Efforts, it is understood that such responsibilities and efforts may be carried out or borne on MAGENTA’s behalf by its Sublicensees or Contractors. 

5. Development. MAGENTA, at its sole cost, shall be responsible for pursuing preclinical and clinical development, Regulatory Approval and marketing of
Products in the Territory; provided that HDPR shall be responsible for the costs associated with its Research Activities. For the avoidance of doubt, nothing in this Article 5 shall limit MAGENTA’s payment obligations set forth in
Section 6.1.1. 

  
 17 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 6. Supply of Compounds and Products; Technology Transfer. 

6.1 Pre-Clinical Supply. The provisions set forth in this Section 6.1,
including its subsections, relate exclusively to the manufacture of non-GMP quality Antibody-drug conjugate material, Amanitin Toxin Constructs and Amanitin. 

6.1.1 Obligation to Supply. 

(a) General. Subject to the remainder of this Article 6, HDPR, either itself or through its engagement of contractors, will
manufacture and supply MAGENTA with quantities of Antibody-drug conjugate material, Amanitin Toxin Constructs or Amanitin, as requested by MAGENTA and set forth in the Research Plan, sufficient for MAGENTA to perform its pre-clinical development activities set forth in the Research Plan, including any pre-clinical Research Activities. For this purpose, and as more fully set forth in the
Research Plan, HDPR will manufacture and deliver to MAGENTA up to 1g of Amanitin Toxin Construct during the twelve (12) month period immediately following the Effective Date, which could include one (1) or more Linkers or toxins, as
specified in the Research Plan. 
 (b) Fees. Subject to Section 6.1.1(c), in connection with HDPR’s
manufacture and supply of Antibody-drug conjugate material, Amanitin Toxin Constructs or Amanitin as more fully set forth in Section 6.1.1(a), except for [***], MAGENTA shall pay HDPR a flat rate of [***] for such supply
during the [***] period immediately following the Effective Date, plus the reasonable and documented out-of-pocket costs of materials used by HDPR in connection with the
manufacture and supply of building blocks for Antibody-drug conjugate material, Amanitin Toxin Constructs or Amanitin, which costs will not exceed an aggregate amount of [***]. For the avoidance of doubt, if the JSC should decide that, for reasons
of time, [***] shall be performed by HDPR internally, the cost for its production will be set forth separately, but will in no case exceed the aggregate amount for external costs [***] set forth above. In no event will the aggregate amount paid by
MAGENTA pursuant to this Section 6.1.1 (b) during the first [***] period immediately following the Effective Date exceed [***], unless MAGENTA requests that HDPR manufacture and deliver more than 1g of Amanitin Toxin
Construct during the [***] period immediately following the Effective Date. MAGENTA will make such payment to HDPR within [***] of its receipt of an invoice from HDPR therefor, which invoice will be sent within [***] of the Effective Date. 

(c) Supply of Antibody-drug Conjugate Material. With regard to the conjugation of the Amanitin Toxin Constructs to the Antibody to
create Antibody-drug conjugate material (such process, the “Conjugation” and conducting such process “Conjugating”), MAGENTA will decide, at its own discretion, for each batch of Antibody-drug conjugate material
(each such batch, an “ADC Batch”), between the following options: 
  

	 	(i)	 Performance by HDPR. If MAGENTA elects for HDPR to Conjugate an ADC Batch, then MAGENTA will notify HDPR
of such election in writing, which writing and any subsequent writing pursuant to which MAGENTA requests additional Antibody-drug conjugate material, will also set forth the amount of Antibody-drug conjugate material that MAGENTA requires in
connection with each such ADC Batch (such amount not to exceed [***] per ADC Batch) and the requested delivery date for each such ADC Batch, which will not be sooner than [***] from the date of each such writing (each such writing, an
“Order”). HDPR will promptly notify MAGENTA in writing of the amount of Antibody that HDPR requires to Conjugate the requested amount of Antibody-drug conjugate material for such

  
 18 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

	 	
ADC Batch and the date by which HDPR must receive such Antibody in order for HDPR to meet MAGENTA’s requested delivery date as set forth in the Order, and MAGENTA will be responsible for
[***]. HDPR will Conjugate the ADC Batch to the requested amount of Antibody-drug conjugate material and deliver such material to MAGENTA via World Courier (DDP, Incoterms 2010) no later than the requested delivery date (or such later date agreed to
by the Parties pursuant to the proviso in the immediately preceding sentence). MAGENTA will make a onetime payment of [***] for each ADC Batch. 

  

	 	(ii)	Performance by MAGENTA. If MAGENTA decides to Conjugate or have Conjugated ADC Batches itself, then MAGENTA will notify HDPR of such election in writing and HDPR will promptly (1) effect a Transfer to
MAGENTA or its Designee all HDPR Know-How necessary to conduct Conjugation, including all associated methods, standards and processes, including with respect to the HDPR
Know-How set forth on Schedule 6.1.1(c)(ii) hereto (the “Non-GMP Partial Manufacturing Process”) and (2) provide MAGENTA or its designee
with reasonable assistance in implementing the Non-GMP Partial Manufacturing Process at facilities designated by MAGENTA or its designee (such Transfer and implementation assistance, the “Non-GMP Partial Manufacturing Technology Transfer”). As reimbursement for the Non-GMP Partial Manufacturing Technology Transfer, MAGENTA will pay HDPR a one-time fee of [***] after successful completion of the Non-GMP Partial Manufacturing Technology Transfer to MAGENTA. MAGENTA may only use the
Non-GMP Partial Manufacturing Process for the sole purpose of researching, developing, manufacturing and commercializing Compounds and Products. 

(d) Supply of Amanitin Toxin Constructs and Amanitin. Notwithstanding anything to the contrary in
Section 6.1.1(a), and in addition to the manufacturing and supply obligations set forth in Sections 6.1.1(a)-(c), if MAGENTA desires that HDPR manufacture and supply MAGENTA with more than [***] of
Antibody-drug conjugate material, Amanitin Toxin Constructs or Amanitin, then the JSC may request, from time to time during the Agreement Term, pursuant to a written order issued to HDPR, that HDPR supply MAGENTA with such additional supply of
Antibody-drug conjugate material, Amanitin Toxin Construct or Amanitin and, in such event, HDPR will deliver to the JSC a written proposal setting forth the costs of such additional supply. The JSC will determine whether or not to accept HDPR’s
proposal. If the proposal is accepted by the JSC, then HDPR will deliver to MAGENTA the requested amount of Antibody-drug conjugate material, Amanitin Toxin Construct or Amanitin within the corresponding timeline set forth by the JSC. The costs of
such additional Antibody-drug conjugate material, Amanitin Toxin Constructs or Amanitin shall be priced according to the Service Cost List attached hereto as Appendix 2, which will be agreed to by the Parties in good faith following the
Effective Date and, once agreed to, appended to this Agreement. 

  
 19 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 6.1.2 Inability to Supply. 

(a) Should HDPR become aware of facts or circumstances that make it reasonably likely that HDPR will be unable to supply MAGENTA with
quantities of Antibody-drug conjugate material sufficient for MAGENTA to perform its pre-clinical development activities set forth in the Research Plan, including any
pre-clinical Research Activities, then HDPR will promptly notify MAGENTA in writing that it is reasonably likely that HDPR will be unable to satisfy its supply obligations as set forth in
Section 6.1.1, and the Parties will discuss, for a period not to exceed [***], whether to amend HDPR’s supply obligation so that HDPR is only responsible for supplying MAGENTA with Amanitin Toxin Constructs. In the
event that the Parties agree, pursuant to this Section 6.1.2, that HDPR will only be responsible for supplying MAGENTA with Amanitin Toxin Constructs as aforesaid, then HDPR will effect the
Non-GMP Partial Manufacturing Technology Transfer as set forth in Section 6.1.1(c)(ii) to MAGENTA or its Designee and MAGENTA will pay HDPR a
one-time fee of [***], unless HDPR’s inability to supply was primarily caused by factors within its control, in which case MAGENTA will not pay any fee to HDPR for the
Non-GMP Partial Manufacturing Technology Transfer. In the event the Parties dispute, in good faith, whether an event or circumstance was within HDPR’s control, such dispute will be resolved in accordance
with Section 19.2. 
 (b) Should HDPR become aware of facts or circumstances that make it reasonable likely that
HDPR will be unable to supply MAGENTA with quantities of Amanitin Toxin Constructs, Amanitin or Antibody-drug conjugate material sufficient for MAGENTA to perform its pre-clinical development activities set
forth in the Research Plan, then HDPR will promptly notify MAGENTA in writing that it is reasonably likely that HDPR will be unable to satisfy its supply obligations as set forth in Section 6.1.1, and MAGENTA may elect, in
its sole discretion, for HDPR to promptly (i) effect a Transfer to MAGENTA or its Designee of all HDPR Know-How necessary for the (i) Non-GMP Partial
Manufacturing Process and (ii) then-current process for the manufacture of Amanitin Toxin Constructs and Amanitin, including all associated methods, standards and processes, including with respect to the HDPR
Know-How set forth on Schedule 6.1.2(b) hereto ((i)-(ii) collectively, the “Non-GMP Full Manufacturing Process”) and (iii) provide MAGENTA
with reasonable assistance requested by MAGENTA or its Designee to implement the Non-GMP Full Manufacturing Process at facilities designated by MAGENTA or its designee (such Transfer and implementation
assistance, as more fully described herein, the “Non-GMP Full Manufacturing Technology Transfer”). If MAGENTA elects, pursuant to this Section 6.1.2, to cause a Non-GMP Full Manufacturing Technology Transfer, then MAGENTA will pay HDPR a one-time fee of [***] upon successful completion of the
Non-GMP Full Manufacturing Technology Transfer to MAGENTA, unless HDPR’s inability to supply was primarily caused by factors within its control, in which case MAGENTA will not pay any fee to HDPR for the Non-GMP Full Manufacturing Technology Transfer. In the event the Parties dispute, in good faith, whether an event or circumstance was within HDPR’s control, such dispute will be resolved in accordance with
Section 19.2. MAGENTA may only use the Non-GMP Full Manufacturing Process for the sole purpose of researching, developing, manufacturing and commercializing Compounds and Products.

 6.1.3 Further Assistance. In connection with a Non-GMP Partial Manufacturing Technology
Transfer or Non-GMP Full Manufacturing Technology Transfer, HDPR shall: 
 (a) make available, and
will use reasonable efforts to cause its Third Party manufacturers to make available, to MAGENTA (or its Designee, as applicable) from time to time as MAGENTA may request, all manufacturing-related Know-How
and materials directly relating to the Non-GMP Partial Manufacturing Process or Non-GMP Full Manufacturing Process, as 

  
 20 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 
applicable, and all documentation constituting material support, performance advice, shop practice, standard operating procedures, specifications as to materials to be used and control methods,
that are necessary to enable MAGENTA (or its Designee, as applicable) to use and practice the Non-GMP Partial Manufacturing Process or Non-GMP Full Manufacturing
Process, as applicable; 
 (b) cause all appropriate employees and representatives of HDPR and its Affiliates to meet with, and will use
reasonable efforts to cause specified employees of its Third Party manufacturers to meet with, employees or representatives of MAGENTA (or its Designee, as applicable) at the applicable manufacturing facility at mutually convenient times to assist
with the training of the personnel of MAGENTA (or its Designee, as applicable) to the extent reasonably necessary to enable MAGENTA (or its Designee, as applicable) to use and practice the Non-GMP Partial
Manufacturing Process or Non-GMP Full Manufacturing Process, as applicable; and 
 (c) take such
steps, and will use reasonable efforts to cause its Third Party manufacturers to take such steps, as are reasonably necessary to assist MAGENTA (or its Designee, as applicable) in obtaining any necessary licenses, permits or approvals from
Regulatory Authorities with respect to the (i) Conjugation of Antibody-drug conjugate material, with respect to a Non-GMP Partial Manufacturing Technology Transfer and (ii) Conjugation of
Antibody-drug conjugate material and manufacture of Amanitin Toxin Constructs or Amanitin, with respect to a Non-GMP Full Manufacturing Technology Transfer, with respect to each ((i)-(ii)), at the applicable
facilities. 
 6.1.4 Pre-Clinical Supply Terms and Conditions. The terms set forth in
Schedule 6.1.4 will apply to HDPR’s or its Third Party designee’s supply of Antibody-drug conjugate material, Amanitin Toxin Constructs or Amanitin to MAGENTA pursuant to Section 6.1.1. 

6.2 Clinical and Commercial Supply. The provisions set forth in this Section 6.2, including its subsections,
relate exclusively to the manufacture and supply of GMP-quality Amanitin Toxin Constructs and Amanitin. 

6.2.1 JSC Decision. The JSC shall be responsible for determining the Party, Affiliate, Sublicensee or Third Party responsible for the
manufacture and supply of GMP-quality Amanitin Toxin Constructs and Amanitin for GLP toxicology studies and all clinical development and commercial uses. For the avoidance of doubt, Amanitin Toxin Constructs
and Amanitin that is suitable for use in GLP toxicology studies will be considered GMP-quality material under this Agreement. In making such decision, the JSC will consider all relevant factors, including
applicable GMP requirements and delivery timing, and, based on such considerations, will choose from one (1) of the following options: 

(a) HDPR, through its existing relationship with [***] (or any successor Third Party engaged by HDPR), will manufacture and supply MAGENTA with
Amanitin Toxin Constructs and Amanitin for the production of Antibody-drug conjugate material for GLP toxicology studies and all clinical development and commercial uses; provided that (a) this option may only be selected during the
first [***] period following the Effective Date, (b) the Parties will in good faith establish the terms and conditions of a definitive written agreement by which HDPR will supply MAGENTA and (c) the Parties, pursuant to
Section 6.3, enter into an appropriate quality agreement; 

  
 21 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 (b) [***], or its successor, will directly supply MAGENTA with Amanitin Toxin Constructs and
Amanitin for the production of Antibody-drug conjugate material for the performance of GLP toxicology studies and all clinical development and commercial uses; provided that the JSC may only select this option if HDPR and [***] or its
successor have executed a mutually acceptable agreement allowing [***] or its successor to directly supply MAGENTA as aforesaid; or 
 (c) If
MAGENTA has exercised its Development Option Right for at least one (1) Exclusive Research Target, then the JSC may elect for HDPR to effect a Transfer to MAGENTA or its designee (which designee may be a MAGENTA Affiliate, a Sublicensee or a
Third Party manufacturer, hereafter the “Designee”) of all Know-How Controlled by HDPR or [***], or its successor, as applicable, that is necessary for the then-current process for the
manufacture of Amanitin Toxin Constructs and Amanitin in GMP-quality, including all associated methods, standards and processes, including with respect to the HDPR or [***] (or its successor) Know-How set forth on Schedule 6.2.1(c) (the “GMP Full Manufacturing Process”). In such event, HDPR will provide MAGENTA with reasonable assistance requested by MAGENTA or its Designee to
implement the GMP Full Manufacturing Process at facilities designated by MAGENTA or its designee (such Transfer and implementation assistance, as more fully described herein, the “GMP Full Manufacturing Technology Transfer”). The
Parties will negotiate in good faith an agreement for the GMP Full Manufacturing Technology Transfer (such agreement, the “GMP Full Manufacturing Technology Transfer Agreement” or “GFMTTA”), setting forth the fees
to be paid by MAGENTA to HDPR as a compensation for the GMP Full Manufacturing Technology Transfer. The Parties envisage the conclusion of the GFMTTA by [***]. If the Parties are unable to agree on the terms of the GFMTTA before this date, then the
Parties will continue negotiations on the terms of the GFMTTA and, in parallel, the Parties will initiate the GMP Full Manufacturing Technology Transfer upon MAGENTA’s request for the duration of three (3) months against payment of an
initiation fee of [***] by MAGENTA, [***]. After completion of the GMP Full Manufacturing Technology Transfer, MAGENTA, either itself or through a Contractor, will be responsible for the manufacture and supply Amanitin Toxin Constructs and Amanitin
for GLP toxicology studies and all clinical development and commercial uses. MAGENTA or its Designee may only use the GMP Full Manufacturing Process for the sole purpose of researching, developing, manufacturing and commercializing Compounds and
Products. 
 6.3 Quality Agreement. If, pursuant to Section 6.2.1(a), the JSC selects HDPR to be responsible
for manufacturing and supplying MAGENTA with GMP-quality Amanitin Toxin Constructs or Amanitin for GLP toxicology studies or clinical development and commercial uses, then the Parties will enter into a
mutually acceptable quality agreement with respect to such manufacture and supply no later than [***] before HDPR starts manufacturing and supplying the first batch of Amanitin Toxin Constructs and Amanitin for the production of Antibody-drug
conjugate material for such uses. 
 7. Regulatory. 

7.1 Decision-Making. MAGENTA, at its sole cost and acting in its sole discretion, shall be responsible for all regulatory affairs
related to Products in the Territory, including the preparation and filing of applications for Regulatory Approval therefor, as well as any or all governmental approvals required to develop, have developed, make, have made, use, have used,
manufacture, have manufactured, import, have imported, sell and have sold Products in a country in the Territory. MAGENTA shall be responsible for pursuing, compiling and submitting all regulatory filing documentation for, and interacting with
Regulatory Authorities in connection with, 

  
 22 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 
all Products in all countries in the Territory. MAGENTA or its Sublicensees shall own and file in their discretion all regulatory filings and Regulatory Approvals for all Products in all
countries of the Territory. MAGENTA, at its sole cost, shall report to appropriate authorities, in accordance with Applicable Law, all adverse events related to use of the Products in the Territory. 

7.2 Right of Reference. HDPR hereby grants MAGENTA a license and right of reference, as may be necessary (both together hereafter
referred to as “Reference License”), with respect to the CMC and manufacturing components of the Regulatory Approvals, investigational new drug applications and other regulatory data or documentation (including drug master files)
relating to Amanitin Toxin Constructs that HDPR or its Affiliates may Control, with the right to grant sublicenses and further rights of reference in accordance with Section 3.7, for the purpose of developing, having
developed, making, having made, using, having used, manufacturing, having manufactured, importing, having imported, selling and having sold Compounds and Products in the Field in the Territory (the “Reference Purpose”). The
Reference License shall be exclusive with respect to the Reference Purpose. HDPR shall execute any documentation reasonably requested by MAGENTA to effect such right of reference and shall use commercially reasonable efforts to cause its Third Party
contract manufacturers to grant such right of reference and execute such documentation. In furtherance of the foregoing, in the event HDPR or [***] (or its successors) is supplying MAGENTA with GMP-quality
Amanitin Toxin Constructs or Amanitin pursuant to Sections 6.2.1(a) or 6.2.1(b), HDPR will (a) assist MAGENTA in connection with understanding HDPR’s or [***] (or its successor’s) then-current contract manufacturing
process, including using commercially reasonable efforts to secure for MAGENTA the ability to visit and inspect the facilities of HDPR’s Third Party contractor manufacturers, including [***] (and its successors); and (b) assist MAGENTA in
responding to, and use commercially reasonable efforts to cause its Third Party contract manufacturers, including [***] (and its successors) to assist MAGENTA in responding to, questions from Regulatory Authorities with respect to any regulatory
filings or submissions made by MAGENTA that reference HDPR’s or its Third Party contractor manufacturers’ (including [***] and its successors) Regulatory Approvals or other regulatory data or documentation, including investigational new
drug applications, drug master files and biologies master files. In connection with the foregoing, the JSC will decide whether the Parties should enter into a formal agreement memorializing the Parties’ rights and obligations with respect to
the foregoing Know-How Transfer, including the resources required for such Transfer. If the JSC decides that such a formal agreement should be executed, then the Parties will have [***] to execute such formal
agreement. If the Parties are unable to execute such formal agreement within such [***] period, then the matter will be resolved pursuant to Section 19.2. 

8. Commercialization. MAGENTA, at its own expense, shall have sole responsibility and decision-making authority for the marketing, promotion, sale and
distribution of Products in the Territory. 
 9. Payments. 

9.1 Research and Manufacturing Payments. 

9.1.1 Technology Fee. Within [***] of Effective Date, in consideration of the non-exclusive
license grant set forth in Section 3.1.1, MAGENTA shall pay to HDPR a fee equal to [***], which fee will cover the first [***] of the Technology Research Term. If MAGENTA elects to extend the Technology Research Term for an
additional [***], as provided in Section 2.3.1, [***], then MAGENTA will pay HDPR an additional [***] for each such extension prior to the anniversary of the Effective Date. 

  
 23 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 9.1.2 Research Target Fee and Research Target Extension Fee. 

(a) With respect to a Target for which MAGENTA has exercised its Exclusive Research Option Right pursuant to
Section 3.3, MAGENTA shall pay to HDPR a fee (the “Research Target Fee”) equal to [***] within [***] after receiving written confirmation from the Trusted Person that such Target is not a Blocked Target. An
additional [***] is due upon [***] of MAGENTA’s exercise of the Exclusive Research Option Right for the corresponding Target (the “Research Target Extension Fee”). For the avoidance of doubt, the Research Target Fees for the
Initial Targets will be paid by MAGENTA within [***] after the Effective Date, and the Research Target Extension Fees for the Initial Targets is due on the first anniversary of the Effective Date. 

(b) Notwithstanding the foregoing, no Research Target Fee or Research Target Extension Fee shall be paid by MAGENTA with respect to the fourth
Target for which MAGENTA exercises its Exclusive Research Option Right. 
 (c) If, on an Exclusive Research Target-by-Exclusive Research Target basis, MAGENTA elects to terminate, pursuant to Section 18.2.1 or Section 18.2.3, the exclusive license granted to it
pursuant to Section 3.5 with respect to an Exclusive Research Target, then MAGENTA will have no obligation to pay to HDPR the Research Target Extension Fee with respect to such terminated Exclusive Research Target, so long
as such Research Target Extension Fee has not already become payable by MAGENTA for such Exclusive Research Target. For reasons of clarity, in case of termination of the exclusive license for an Exclusive Research Target as aforesaid, already paid
Research Target Fees will not be reimbursed, neither in total nor partially by HDPR. 
 (d) Should MAGENTA elect its Development Option Right
with respect to an Exclusive Research Target before expiration of the respective Target Research Term, MAGENTA shall receive a credit [***]. For example, [***]. 

9.1.3 Schedule for Research Payments. The following schedule shall illustrate the fees to be paid by MAGENTA pursuant to Sections
9.1.1 and 9.1.2: 
  

			
	 Technology Fees
	  	
	 [***]
	  	 [***]

	 [***]
	  	 [***]

		
	 Research Target Fees
	  	
	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

 9.2 Development Payments. 

9.2.1 Development Option Fee for MAGENTA Development Option. For each Exclusive Research Target, within [***] of MAGENTA exercising its
Development Option Right for such Exclusive Research Target, MAGENTA shall pay to HDPR a fee (each, a “Development Option Fee”) in the amount of [***]. 

  
 24 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 9.2.2 Milestone IND-Enabling Studies. Within
[***] days of MAGENTA first initiating an IND-Enabling Study for the first Development Target, MAGENTA will pay a one-time fee in the amount of [***]. For the avoidance
of doubt, the milestone described in this Section 9.2.2 shall be payable the one-time only. 

9.2.3 Development Events. 

(a) For each Development Target, MAGENTA shall pay up to a total of [***] upon achievement of the following development events by a Product
directed toward such Development Target (each, a “Development Milestone”): 
  

					
	 	  	(In Million USD)
	 Development Event
	  	1st Indication	 	2nd Indication
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]

 (b) Within [***] of the achievement of a Development Milestone, MAGENTA shall notify HDPR of such achievement
and pay to HDPR the amount associated with achievement of such Development Milestone. 
 (c) The Development Milestone payments in the table
above shall be payable by MAGENTA to HDPR upon the first achievement of each such Development Milestone for the first Product directed toward a Development Target that achieves the Development Milestone, but not for any subsequent Products directed
to the same Development Target that achieves the same Development Milestone. If development of a Product directed toward a Development Target is discontinued before such Product has achieved all of the foregoing Development Milestones, then
Development Milestones achieved by any subsequent Product directed toward such Development Target shall be waived for any previously paid Development Milestones, but not for any previously unpaid Development Milestones. 

(d) With respect to Development Milestones that may be triggered by a Product upon achievement of such Development Milestones by such Product
in a second Indication, the payment of the Development Milestone for the first Indication shall always precede payment for the second Indication. By way of example, [***]. 

9.3 Sale Payments. 
 9.3.1
Sales Events. For each commercialized Product, MAGENTA shall pay up to a total of [***] upon achievement of the following sale levels for a Product (each, a “Sales Milestone”). 

 

			
	 Sales Event
	  	(In Million USD)
	 [***]
	  	[***]
	 [***]
	  	[***]

 9.3.2 Limitation. The set of Sale Milestone payments in the table above shall be payable by MAGENTA to
HDPR upon the first achievement of each such Sales Milestone for the first Product directed toward a Development Target, but not for any subsequent Products directed toward such same Development Target that achieves the same Sales Milestone. 

  
 25 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 9.4 Royalty Payments. 

9.4.1 Royalty Rate; Royalty Term. MAGENTA shall pay HDPR royalties at a rate of [***] of aggregate Calendar Year Net Sales of Products,
on a Product-byProduct and country-by-country basis (the “Royalty Rate”), until the expiry of the Royalty Term for a Product in a country. Thereafter,
the licenses with respect to such Product in such country shall be fully paid-up, royalty-free, perpetual and irrevocable in accordance with Section 18.3.3(a). 

9.4.2 No Valid Claim. If no Valid Claim of any Patent Rights included in the HDPR IP Rights or Joint IP Rights Covers the using,
selling, offering for sale or importing of a Product in a country, then the Royalty Rate shall be reduced to [***] of aggregate Calendar Year Net Sales of such Product in such country. 

9.4.3 Third Party Payments. HDPR shall be responsible for all payment and other obligations related to Products and HDPR IP Rights set
forth in its agreements with Third Parties. Subject to Section 9.4.5, MAGENTA shall be entitled to deduct [***] of any Deductible Third Party Payments made by MAGENTA or its Sublicensees from royalties owed on Net Sales of
Products; provided that MAGENTA shall not be entitled to take this deduction with respect to a Product in a country if MAGENTA has reduced the royalties owed under this Agreement under Section 9.4.2 with respect to
such Product in such country. 
 9.4.4 Buy-Out Option. On a Product-by-Product basis, HDPR hereby grants MAGENTA and its Sublicensees the option to reduce the Royalty Rates set forth in Section 9.4.1 (the “Buy-Out Option”) by sending a written notice of such election to HDPR (the “Buy-Out Option Exercise Notice”) and making a one-time payment to HDPR within [***] of the date of such notice (the “Buy-Out Option Fee”) as set forth below. 

(a) The Buy-Out Option Exercise Fee amounts to [***] in case that HDPR receives both the Buy-Out Option Exercise Notice and payment of the Buy-Out Option Fee prior to Initiation of a Phase II Clinical Study for a certain Product. 

(b) The Buy-Out Option Exercise Fee amounts to [***] in case that HDPR receives both the Buy-Out Option Exercise Notice and payment of the Buy-Out Option Fee prior to Initiation of a Phase III Clinical Study for a certain Product. 

In both cases (a) and (b) above the Royalty Rates for such Product shall be reduced from [***] of aggregate Calendar Year Net Sales of
such Product in all countries in the Territory. [***]. [***]. 
 9.4.5 Royalty Floor. Except for the case of No Valid Claim as set
forth in Section 9.4.2, in no event shall the total royalty payable by MAGENTA to HDPR for any Product in any country be less than [***] after any deductions allowed pursuant to Section 9.4.3.
MAGENTA shall have the right to carry forward as offsets against future royalties payable to HDPR any amounts that, but for the foregoing limitations, MAGENTA and its Sublicensees would have been entitled to deduct from any royalty payable to HDPR
under this Agreement. 

  
 26 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 10. Accounting and Reporting. 

10.1 Timing of Royalty Payments. MAGENTA shall calculate royalties on Net Sales Calendar Quarterly, and MAGENTA shall pay any royalties
owed to HDPR pursuant to Section 9.4.1 on account of such Net Sales within [***] after the end of the applicable Calendar Quarter, with such payment to be made to the banking account set forth under
Section 10.3. Each payment of royalties due to HDPR will be accompanied by a statement of the amount of Net Sales of each Product in each country in the Territory during the applicable Calendar Quarter and a calculation of
the amount of royalty payment due on such Net Sales for such Calendar Quarter. 
 10.2 Payment Modalities. All payments to HDPR under
this Agreement will be made by MAGENTA by deposit of Dollars in the requisite amount to the bank account listed in Section 10.3. For the purpose of calculating any sums due under this Agreement (including the calculation of
Net Sales expressed in currencies other than Dollars), MAGENTA will convert any amount expressed in a foreign currency into Dollar equivalents using its own or its Sublicensee’s standard conversion methodology consistent with Accounting
Standards. MAGENTA will have the right to offset any amounts that are owed by HDPR to MAGENTA and are undisputed or determined by a legally binding court order against any payments owed by MAGENTA, if any, under this Agreement. 

10.3 Bank Account. All payments due by MAGENTA to HDPR under this Agreement will be made to the following banking account (or such other
banking account as HDPR may designate to MAGENTA from time to time in writing): 
 [***] 

10.4 Late Payment. Any payment under this Agreement that is not paid on or before the date such payment is due shall bear interest, to
the extent permitted by Applicable Law, at [***] above the US prime rate of interest, as reported by the Wall Street Journal, calculated on the number of days such payment is overdue. 

11. Taxes. 
 11.1 Responsibility.
HDPR shall provide such information and documentation to MAGENTA as are reasonably requested by MAGENTA to determine if any withholding taxes apply to any payments to be made by MAGENTA to HDPR. Solely to the extent that Applicable Laws require
that taxes be withheld with respect to any payments by MAGENTA to HDPR under this Agreement, MAGENTA will: (a) deduct those taxes from the remittable payment, (b) pay the taxes to the proper taxing authority, and (c) send evidence of
the obligation together with proof of tax payment to HDPR on a reasonable and timely basis following that tax payment. Each Party agrees to cooperate with the other Party in claiming refunds or exemptions from such deductions or withholdings under
any relevant agreement or treaty which is in effect. The Parties shall discuss applicable mechanisms for minimizing such taxes to the extent possible in compliance with Applicable Laws. HDPR will pay any and all taxes levied on account of all
payments it receives under this Agreement. 
 11.2 Cooperation. The Parties shall cooperate in accordance with Applicable Laws to minimize
indirect taxes (such as value added tax, sales tax, consumption tax and other similar taxes) in connection with this Agreement. 

  
 27 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 12. Financial Auditing. 

12.1 HDPR Right to Audit. MAGENTA shall keep, and shall require its Sublicensees to keep, full, true and accurate books of account and
records containing all particulars that may be necessary for the purpose of calculating all royalties payable under this Agreement. Such books and records will be retained by MAGENTA and its Sublicensees until the later of (a) [***] after the end of
the period to which such books and records pertain or (b) for such longer period as may be required by Applicable Law. Such books and records shall be kept at their principal place of business. At the expense of HDPR, upon at least [***] to
MAGENTA or its Sublicensees, as applicable, HDPR has the right to engage a reputed public accounting firm to perform, on behalf of HDPR, an audit of the books and records that are maintained by MAGENTA and its Sublicensees pursuant to this
Section 12.1 to ensure the accuracy of all royalty reports and payments made pursuant to this Agreement; provided that, prior to commencing any such audit, such accounting firm shall be required to enter into a
confidentiality and non-disclosure agreement with MAGENTA or its Sublicensees, as applicable, that requires such accounting firm to maintain in confidence and not disclose (except as expressly provided for in
this Section 12.1) any information learned by such accounting firm during such audit. Such audits may not (a) be conducted for any Calendar Quarter more than [***] after the end of such Calendar Quarter, (b) be
conducted more than once in any [***] period or (c) [***]. Such examinations shall occur during regular business hours in such a manner as to not interfere with MAGENTA’s or its Sublicensees’ normal business activities. Results of any
audit under this Section 12.1 shall be made available to both MAGENTA and HDPR pursuant to a written report. Such written report shall only contain the amounts that the public accounting firm believes to be due and payable
hereunder, including details concerning any discrepancy from the amount paid and potential reasons for such discrepancy, but shall contain no other information of MAGENTA or its Sublicensees. The results of such audits, including the written report
provided pursuant to this Section 12.1, shall be the Confidential Information of MAGENTA. 
 12.2 Overpayments
and Underpayments. If the audit reveals an overpayment, such overpayment shall be credited against future royalty payments owed to HDPR under this Agreement or, if no future royalty payments are owed to HDPR under this Agreement, then HDPR shall
reimburse MAGENTA, as applicable, for the amount of such overpayment within [***] of receiving the accounting firms written report pursuant to Section 12.1. If the audit reveals an underpayment, MAGENTA shall make such
underpayment with the next royalty payment or, if no future royalty payments are owed to HDPR, MAGENTA shall reimburse HDPR for the amount of the underpayment within [***] of receiving the accounting firms written report pursuant to
Section 12.1. MAGENTA shall pay for the reasonable and documented costs of such audit only if MAGENTA made an underpayment that exceeds [***] of the aggregate amount of royalty payments owed with regard to the royalty
statements subject of the audit. Underpayments that are not paid when due shall bear interest in accordance with Section 10.4. 

13. Intellectual Property. 
 13.1
Background IP. As between the Parties, (a) MAGENTA will retain ownership of all rights, title and interests in, to and under all MAGENTA IP Rights Controlled by MAGENTA prior to the Effective Date or Controlled by MAGENTA
during the Agreement Term but that are not generated in the performance of the Research Activities contemplated under this Agreement and (b) HDPR will retain ownership of all rights, title and interests in, to and under the HDPR IP Rights
Controlled by HDPR prior to the Effective Date or Controlled by HDPR during the Agreement Term but that is not generated in the performance of the activities contemplated under this Agreement. 

  
 28 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 13.2 Ownership of Inventions. Except as otherwise expressly provided herein, ownership
of all inventions and discoveries governed by this Agreement shall be determined based on inventorship, and inventorship shall be determined in accordance with U.S. patent law. 

13.2.1 MAGENTA IP Improvements. As between the Parties, MAGENTA shall be the sole owner of the Improvements solely related to MAGENTA IP
Rights (the “MAGENTA IP Improvements”). 
 13.2.2 HDPR IP Improvements. As between the Parties, HDPR shall be the
sole owner of the Improvements solely related to HDPR IP Rights (the “HDPR IP Improvements”). HDPR IP Improvements shall be included under the rights and licenses granted by HDPR to MAGENTA and its Affiliates in accordance with
Section 3. 
 13.2.3 Joint IP Rights. The term “Joint IP Rights” means all Improvements
that are neither MAGENTA IP Improvements nor HDPR IP Improvements. As between the Parties, MAGENTA shall be the sole owner of the Joint IP Rights. 

13.3 German Statute on Employee’s Inventions. In accordance with the German Statute on Employees’ Inventions, each Party
agrees to claim the unlimited use of any invention conceived, reduced to practice, developed, made or created in the performance of, or as a result of, any Research Activities by its German employees or any other German Person acting on its behalf.
The Party which is the ultimate assignee of the German employee’s or other Person’s invention under this Agreement will reimburse the other Party for the royalty payable according to statutory provisions or negotiated with the employee or
other Person, provided that such reimbursement will not exceed a payment equal to a royalty rate of [***] on Net Sales for an invention. 

13.4 Trademarks. MAGENTA shall own all trademarks, services marks, trade names, product names, logos and all other indicia of source and
origin, together with all goodwill related thereto, used on or in connection with Products in the Territory (collectively, “Product Marks”), and shall, at its sole cost and acting in its sole discretion, be responsible for the
procurement, maintenance, enforcement and defense of all Product Marks in the Territory. MAGENTA shall have the right to obtain from the World Health Organization International Nonproprietary Name Committee and the US Adopted Names Council a generic
name for the Products. 
 13.5 Right to Handle the Patents. 

13.5.1 HDPR IP Rights. HDPR shall, at its sole cost and acting in its sole discretion, be responsible for Handling the Patent Rights
included in the HDPR IP Rights and HDPR IP Improvements. HDPR shall promptly provide MAGENTA with copies of any material official correspondence to or from patent offices regarding the Patent Rights included in the HDPR IP Improvements. HDPR shall
provide MAGENTA with a reasonable opportunity to review and comment on material filings relating to such Patent Rights before such filings are submitted to any relevant patent office or governmental authority, and shall give reasonable, good faith,
consideration to comments offered by MAGENTA with respect thereto in any final filings submitted by HDPR to any relevant patent office or governmental authority; provided that HDPR shall have the final decision with respect thereto.

  
 29 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 13.5.2 MAGENTA IP Rights. 

(a) MAGENTA shall, at its sole cost and acting in its sole discretion, Handle all Patent Rights included in the MAGENTA IP Rights, MAGENTA IP
Improvements and Joint IP Rights; provided that MAGENTA shall provide HDPR with a reasonable opportunity to review and comment on material filings relating to Patent Rights including in the Joint IP Rights before such filings are
submitted to any relevant patent office or governmental authority and shall give reasonable, good faith, consideration to comments offered by HDPR with respect thereto in any final filings submitted by MAGENTA to any relevant patent office or
governmental authority; provided that MAGENTA shall have the final decision with respect thereto. MAGENTA shall promptly provide HDPR with copies of any material official correspondence to or from patent offices regarding the Patent
Rights included in the Joint IP Rights. 
 (b) Should MAGENTA decide that it does not desire to Handle a Patent Right included in the Joint
IP Rights in a country in the Territory, it shall promptly advise HDPR thereof. At the written request of HDPR, MAGENTA shall, at no cost to HDPR, assign such Patent Rights in such country to HDPR, and HDPR may thereafter Handle such Patent Right at
HDPR’s own cost, to the extent that HDPR desires to do so. 
 13.6 Infringement. 

13.6.1 Notification. Each Party shall promptly provide written notice to the other Party during the Agreement Term of any (a) known
infringement or suspected infringement by a Third Party of any Patent Rights included in the HDPR IP Rights, HDPR IP Improvements or Joint IP Rights or (b) known or suspected unauthorized use or misappropriation by a Third Party of Know-How included in the HDPR IP Rights, HDPR IP Improvements or Joint IP Rights, and shall provide the other Party with all evidence in its possession supporting such infringement or unauthorized use or
misappropriation. 
 13.6.2 Right to Enforce. MAGENTA shall have the sole right and option, but not the obligation, to bring an
infringement action for suspected infringement of the Patent Rights or Know-How included in the MAGENTA IP Rights, MAGENTA IP Improvements or Joint IP Rights (other than with respect to Patent Rights included
in the Joint IP Rights assigned to HDPR pursuant to Section 13.5.2(b)). [***]. HDPR shall reasonably assist MAGENTA (at MAGENTA’s expense) in any such infringement action if so requested, including by being named or
joined as a plaintiff to such action. In the event that either Party learns of an infringement action for suspected infringement of the Patent Rights or Know-How included in the HDPR IP Rights or HDPR IP
Improvements that (a) relates to the development, manufacture or sale of a product that is or is reasonably expected to be competitive to a Product and (b) does not and is not reasonably expected to infringe any of the Patent Rights or Know-How included in the MAGENTA IP Rights, MAGENTA IP Improvements or Joint IP Rights ((a)-(b), a “Competitive Infringement”), then the Party that first learns of such Competitive Infringement will
notify the other Party thereof in writing. [***]. 
 13.6.3 Damages. In the event that MAGENTA exercises the rights conferred in
Section 13.6.2 and recovers any damages or other sums in such infringement action, or in settlement thereof, such damages or other sums recovered shall (a) with respect to damages or other sums recovered on account of
infringement of the Patent Rights included in the MAGENTA IP Rights and MAGENTA IP Improvements, be solely retained by MAGENTA, (b) with respect to damages or other sums recovered on account of infringement of the Patent Rights included in the
Joint IP Rights, first be applied to all reasonable out-of-pocket costs and expenses incurred by the Parties in connection with the action relating to such infringement
(including reasonable attorneys’ fees), with the remainder shared [***] and (c) with respect to damages or other sums 

  
 30 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 
recovered on account of MAGENTA’s step-in enforcement rights with respect to a Competitive Infringement, first be applied to all reasonable out-of-pocket costs and expenses incurred by the Parties in connection with the action relating to such infringement (including reasonable attorneys’ fees), with the
remainder shared [***]. In the event that HDPR exercises its first right to bring an infringement action for a Competitive Infringement pursuant to Section 13.6.2 and recovers any damages or other sums in such infringement
action, or in settlement thereof, such damages or other sums recovered shall first be applied to all reasonable out-of-pocket costs and expenses incurred by the Parties
in connection therewith (including reasonable attorneys’ fees), with the remainder shared [***], respectively. If any recovery is insufficient to cover all costs and expenses of the Parties as aforesaid, such recovery shall be shared in
proportion to the total of such costs and expenses incurred by each Party. 
 14. Representations and Warranties. 

14.1 Mutual Representations and Warranties. Each Party represents and warrants to the other Party that, as of the Effective Date: 

(a) it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other
power and authority to enter into this Agreement, and to carry out the provisions hereof; 
 (b) it is duly authorized to execute and deliver
this Agreement, and to perform its obligations hereunder, and the Person or Persons executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate action; and 

(c) this Agreement is legally binding upon it and enforceable in accordance with its terms. 

14.2 Representations and Warranties of HDPR. HDPR represents and warrants to MAGENTA, as of the Effective Date, that: 

(a) it is the sole and exclusive owner of all HDPR IP Rights, free of any lien or security interest; 

(b) it has the power and authority to grant and license to the MAGENTA all of the rights, title and interests purported to be granted herein;

 (c) no Third Party has challenged the ownership, scope, duration, validity, enforceability, priority or right to use any HDPR IP Rights;

 (d) to HDPR’s knowledge, the use, development, manufacture or commercialization by HDPR or MAGENTA (or their respective Affiliates,
Sublicensees or subcontractors, as applicable) of the Compound or Products do not infringe any issued patent of any Third Party; 
 (e) there
is no (i) claim, demand, suit, proceeding, arbitration, inquiry, investigation or other legal action of any nature (whether civil, criminal, regulatory or otherwise) pending or, to HDPR’s knowledge, threatened against HDPR or any of its
Affiliates or (ii) judgment or settlement against or owed by HDPR or any of its Affiliates, in each case ((i)-(ii)), with respect to the HDPR IP Rights or any Amanitin Toxin Construct; 

  
 31 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 (f) to HDPR’s knowledge, no Third Party is infringing any HDPR IP Rights; 

(g) HDPR has not intentionally failed to furnish MAGENTA with any information requested by MAGENTA, or intentionally concealed from MAGENTA any
information in its possession, regarding the safety of Amanitin Toxin Constructs; and 
 (h) neither HDPR nor its Affiliates, nor any of
their employees, officers, subcontractors or consultants who have rendered services relating to the Compounds or Products (a) has ever been debarred or is subject to debarment or convicted of a crime for which an entity or person could be
debarred by the FDA under 21 U.S.C. Section 335a or (b) have ever been under indictment for a crime for which a person or entity could be so debarred. 

14.3 Covenants of HDPR. HDPR covenants to MAGENTA that, from and after the Effective Date and during the Agreement Term of this
Agreement: 
 (a) it shall not, and shall cause its Affiliates to not, assign, transfer, convey, option or grant any rights to the HDPR IP
Rights or HDPR IP Improvements that are inconsistent with or would conflict with or limit the scope of any of the rights or licenses granted to MAGENTA hereunder; and 

(b) it shall not, and shall cause its Affiliates to not (i) license, sell, assign or otherwise transfer to any Person (other than to a
successor in interest as permitted under Section 19.3) any HDPR IP Rights or HDPR IP Improvements (or agree to do any of the foregoing) or (ii) incur or permit to exist, with respect to any HDPR IP Rights or HDPR IP
Improvements, any lien, encumbrance, charge, security interest, mortgage, liability, grant of license to Third Parties or other restriction (including in connection with any indebtedness) that would reduce or adversely affect MAGENTA’s rights
hereunder. 
 15. Indemnification. 

15.1 Indemnification by MAGENTA. MAGENTA shall indemnify, hold harmless and defend HDPR and its Affiliates, and its and their directors,
officers, employees and agents from and against any and all losses, expense and, cost of defense (including reasonable attorneys’ fees, witness fees, damages, judgments, fines and amounts paid in settlement) arising in connection with any
claims, suits, proceedings or other causes of action brought by a Third Party to the extent arising out of (a) a breach by MAGENTA or its Affiliates of its representations, warranties and covenants set forth in
Section 14 or a breach of Section 17, (b) the gross negligence, willful misconduct or fraud of MAGENTA or its Affiliates and (c) the development or use of any Compound or Product by MAGENTA or
its Affiliates, with respect to each ((a)-(c)), except to the extent such losses, expenses, costs and amounts are due to the gross negligence, willful misconduct or fraud of HDPR or its Affiliates. 

15.2 Indemnification by HDPR. HDPR shall indemnify, hold harmless and defend the MAGENTA Group (which, for purposes of this
Section 15.2 only, will include Affiliates of MAGENTA, whether or not such Affiliates have been granted a sublicense hereunder) and its Contractors, directors, officers, employees and agents from and against any and all
losses, expenses and costs of defense (including reasonable attorneys’ fees, witness fees, damages, judgments, fines and amounts paid in settlement) arising in connection with any claims, suits, proceedings or other causes of action brought by
a Third Party to the extent arising out of (a) a breach by HDPR or its Affiliates of its representations, warranties and covenants set forth in Section 14 or a breach of Section 17 and
(b) the gross negligence, willful misconduct or fraud of HDPR or its Affiliates, with respect to each ((a)-(b)), except to the extent such losses, expenses, costs and amounts are due to the gross negligence, willful misconduct or fraud of a
member of the MAGENTA Group. 

  
 32 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 15.3 Procedure. In the event of a claim by a Third Party against a Person entitled to
indemnification under this Agreement (“Indemnified Party”), the Indemnified Party shall promptly notify the other Party (“Indemnifying Party”) in writing of the claim and the Indemnifying Party shall undertake and
solely manage and control, at its sole expense, the defense of the claim, including any settlement thereof. The Indemnified Party shall, at the Indemnifying Party’s expense, reasonably cooperate with the Indemnifying Party in connection with
the defense of such claim and may, at its option and expense, be represented in any such action or proceeding by counsel of its choice. The Indemnifying Party shall not be liable for any litigation costs or expenses incurred by the Indemnified Party
without the Indemnifying Party’s written consent. The Indemnifying Party shall not settle any such claim unless such settlement fully and unconditionally releases the Indemnified Party from all liability relating thereto, unless the Indemnified
Party agrees in writing otherwise. 
 16. Limitation of Liability; Disclaimer 

16.1 Limitation of Liability. EXCEPT IN CONNECTION WITH (A) BREACHES OF SECTION 17 BY HDPR OR ITS AFFILIATES, (B) THE
GROSS NEGLIGENCE, WILLFUL MISCONDUCT OR FRAUD OF HDPR OR ITS AFFILIATES OR (C) LOSSES AND CLAIMS PURSUANT TO SECTION 15.2, THE LIABILITY OF HDPR UNDER THIS AGREEMENT IS LIMITED TO [***]. 

16.2 Consequential Damages. EXCEPT IN CONNECTION WITH (A) BREACHES OF SECTION 17 BY A PARTY OR ITS AFFILIATES, (B) THE
GROSS NEGLIGENCE, WILLFUL MISCONDUCT OR FRAUD OF A PARTY OR ITS AFFILIATES OR (C) LOSSES AND CLAIMS PURSUANT TO SECTION 15, IN NO EVENT SHALL EITHER HDPR OR THE MAGENTA GROUP BE LIABLE FOR ANY SPECIAL, INDIRECT, INCIDENTAL, SPECIAL,
EXEMPLARY, PUNITIVE OR CONSEQUENTIAL DAMAGES, INCLUDING LOSS OF PROFITS OR BUSINESS INTERRUPTION, ARISING OUT OF THIS AGREEMENT, WHETHER BASED ON CONTRACT, TORT, STATUTORY DUTY OR ANY OTHER LEGAL THEORY, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH
DAMAGE. 
 16.3 Disclaimer. THE REPRESENTATIONS AND WARRANTIES SET FORTH IN SECTION 14 ARE IN LIEU OF ALL OTHER REPRESENTATIONS
AND WARRANTIES NOT EXPRESSLY SET FORTH HEREIN. HDPR AND MAGENTA DISCLAIM ALL OTHER WARRANTIES, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO EACH OF THEIR RESEARCH, DEVELOPMENT AND COMMERCIALIZATION EFFORTS HEREUNDER, INCLUDING, WHETHER THE PRODUCTS
CAN BE SUCCESSFULLY DEVELOPED OR MARKETED OR THE ACCURACY, PERFORMANCE, UTILITY, RELIABILITY, TECHNOLOGICAL OR COMMERCIAL VALUE, COMPREHENSIVENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE WHATSOEVER OF THE PRODUCTS. 

  
 33 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 17. Obligation Not to Disclose Confidential Information. 

17.1 Non-Use and Non-Disclosure. During the Agreement
Term and for [***] thereafter, a Receiving Party shall (a) keep in confidence and not disclose to any Third Party any Confidential Information provided to it by the Disclosing Party, using the same degree of care in protecting such Confidential
Information as it would use to protect its own information of a similar nature (but in no event, less than a reasonable degree of care) and (b) not use or disclose such Confidential Information other than as expressly provided for in this
Agreement or as reasonably necessary for fulfilling its obligations or exercising its rights under this Agreement. 
 17.2 Permitted
Disclosure. Notwithstanding the obligation of non-use and nondisclosure set forth in Section 17.1, the Parties recognize the need for certain exceptions to this obligation,
specifically set forth below, with respect to press releases, Patent Rights, publications, and certain commercial considerations. To that end, each Party may disclose Confidential Information to the extent such disclosure is: 

17.2.1 in the reasonable opinion of the Receiving Party’s legal counsel, required to be disclosed pursuant to Applicable Law or a valid
order of a court of competent jurisdiction or governmental body; provided that the Receiving Party will first have given prompt written notice to the Disclosing Party so that the Disclosing Party has a reasonable opportunity to take
whatever action it deems necessary to protect its Confidential Information. In the event that no protective order or other remedy is obtained, or the Disclosing Party waives compliance with the terms of this Agreement, the Receiving Party will
furnish only that portion of Confidential Information which the Receiving Party is advised by counsel is legally required to be disclosed; 

17.2.2 made by or on behalf of MAGENTA to Regulatory Authorities as required in connection with any filing, application or request for
Regulatory Approval of a Product in accordance with the MAGENTA’s rights under the terms of this Agreement; provided that reasonable measures will be taken to assure confidential treatment of HDPR’s Confidential Information
to the extent practicable and consistent with Applicable Law; 
 17.2.3 made by or on behalf of the Receiving Party to a patent authority as
may be reasonably necessary or useful for purposes of Handling a Patent Right in accordance with the Receiving Party’s rights under the terms of this Agreement; provided that the Disclosing Party is informed about such disclosure
and reasonable measures will be taken to assure confidential treatment of such Confidential Information, to the extent such protection is available; and 

17.2.4 made by the Receiving Party to its (a) financial and legal advisors who have a need to know the Disclosing Party’s
Confidential Information, (b) its Affiliates or (c) its or their advisors, consultants, clinicians, vendors, service providers, Sublicensees or Contractors as may be necessary or reasonably required in connection with the research,
development, manufacture, commercialization, use or other exploitation of Compounds or Products; provided that such Persons (the “Permitted Recipients”) will be subject to obligations of confidentiality and non-use with respect to such Confidential Information at least as protective to the Disclosing Party as the obligations of confidentiality and non-use of the Receiving Party
pursuant to this Section 17. 
 17.3 Publications. Notwithstanding the obligation of non-use and non-disclosure set forth in Section 17.1, during the Agreement Term, the following provisions shall apply with respect to disclosure by
any Party of Confidential Information relating to the Product in any publication or presentation: 
 (a) Both Parties acknowledge that it is
their policy for the studies and results thereof to be registered and published in accordance with their internal guidelines. 

  
 34 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 (b) A Party (“Publishing Party”) shall provide the other Party with a copy
of any proposed publication or presentation at least [***] (or at least [***] in the case of oral presentations) prior to submission for publication or presentment so as to provide such other Party with an opportunity to recommend any changes it
reasonably believes are necessary to continue to maintain the confidentiality of any Confidential Information contained in such publication or presentation and disclosed by the other Party to the Publishing Party pursuant to this Agreement. The
Publishing Party shall reasonably consider any such recommended changes and will not unreasonably refuse to incorporate any such changes. If such other Party notifies (“Publishing Notice”) the Publishing Party in writing, within
[***] after receipt of the copy of the proposed publication or presentation (or at least [***] in the case of oral presentations), that such publication or presentation, in its reasonable judgment, (i) contains an invention, solely or jointly
conceived or reduced to practice by the other Party, for which the other Party reasonably desires to obtain patent protection or (ii) could be expected to have an adverse effect on the commercial value of the other Party’s Patent Rights, Know-How, Compounds or Products, with respect to each ((i)-(ii)), then the Publishing Party shall prevent such publication or delay such publication for a mutually agreeable period of time. In the case of
inventions, a delay shall be for a period reasonably sufficient to permit the timely preparation and filing of a patent application(s) on such invention, and in no event less than [***] from the date of the Publishing Notice. Notwithstanding the
foregoing, in no event may HDPR or its Affiliates make a publication or presentation with respect to any Compound or Product without first obtaining MAGENTA’s prior written consent. 

(c) On or promptly after the Effective Date, the Parties shall issue a public announcement regarding the execution of this Agreement, to be
previously agreed upon by the Parties and attached hereto as Appendix 3. 
 18. Term and Termination. 

18.1 Commencement and Term. This Agreement shall commence upon the Effective Date and continue for the Agreement Term. 

18.2 Termination. 
 18.2.1
Termination for Breach. In the event a Party (“Breaching Party”) is in material breach of any of its obligations under this Agreement, including under Section 9, the other Party (“Non-Breaching Party”) shall have the right to terminate this Agreement in its entirety in accordance with this Section 18.2.1; provided that, if such material breach
does not constitute a material breach of the payment obligations set forth in Article 9 and relates solely to a specific Product, Non-Exclusive Research Target, Exclusive Research Target or Development
Target, then the Non-Breaching Party shall have the right to terminate this Agreement solely with respect to such Product, Non-Exclusive Research Target, Exclusive
Research Target or Development Target in accordance with this Section 18.2.1. The Non-Breaching Party shall provide written notice to the Breaching Party, which notice shall identify
the breach and the Products, Non-Exclusive Research Targets, Exclusive Research Targets or Development Targets to which such breach relates. The Breaching Party shall have a period of [***] after such written
notice is provided (“Peremptory Notice Period”) to cure such breach. If the Breaching Party has a bona fide dispute as to whether such breach has occurred or has been cured, it will so notify the
Non-Breaching Party in writing, and the Peremptory Notice Period shall be tolled until such dispute is resolved pursuant to Section 19.2. Upon a final determination of breach or
failure to cure, the Breaching Party shall have the remainder of the Peremptory Notice Period to cure such breach. If such breach is not cured within the Peremptory Notice Period, then the Non-Breaching Party
may provide the Breaching Party with a written notice of termination specifying the Products, Non-Exclusive Research Targets, Exclusive Research Targets or Development Targets with respect to which the
Agreement is terminating, which termination will be effective as of the date such written notice is received by the Breaching Party; provided, however, that if such breach is not reasonably curable within such [***] period and
the Breaching Party is using good faith efforts to cure such breach during such [***] period, then the Breaching Party will have an additional [***] to cure such breach. 

  
 35 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 18.2.2 Insolvency. A Party shall have the right to terminate this Agreement, if the
other Party experiences an Insolvency Event; provided, however, that, in the case of any involuntary bankruptcy proceeding, such right to terminate shall only become effective if the Party that incurs the Insolvency Event consents to
the involuntary bankruptcy proceeding or such proceeding is not dismissed within [***] after the filing thereof. 
 18.2.3 Termination by
MAGENTA Without Cause. MAGENTA shall have the right to terminate the Agreement, at any time, in its entirety or on a Non-Exclusive Research
Target-by-Non-Exclusive Research Target, Exclusive Research
Target-by-Exclusive Research Target, Development Target-by-Development Target, Product-by-Product or country-by-country basis, upon (a) [***] prior written notice to HDPR, if
terminating before First Commercial Sale of a Product in a country or (b) [***] prior written notice to HDPR, if terminating after the First Commercial Sale of such Product or a Product directed to such Exclusive Research Target, as applicable, in a
country. By way of example, if First Commercial Sale of a Product has occurred in the EU but not in the US and MAGENTA desires to terminate this Agreement with respect to such Product, then MAGENTA will be required to provide HDPR with [***] prior
written notice to terminate this Agreement with respect to such Product in the EU, but will only be required to provide HDPR with [***] prior written notice to terminate this Agreement with respect to such Product in the US. 

18.3 Consequences of Termination and Expiration. 

18.3.1 Partial Termination. Upon any termination of this Agreement with respect to a Product,
Non-Exclusive Research Target, Exclusive Research Target or Development Targets by HDPR for MAGENTA’s material breach in accordance with Section 18.2.1 or by MAGENTA for
HDPR’s material breach in accordance with Section 18.2.1 or at-will pursuant to Section 18.2.3: 

(a) all rights and licenses granted by a Party to another Party under this Agreement shall terminate immediately on the effective date of
termination with respect to the terminated Product, Non-Exclusive Research Target, Exclusive Research Target or Development Target, as applicable; provided that MAGENTA’s grant of the
Grant-Back License to HDPR shall not terminate; 
 (b) with respect to a terminated Product, should MAGENTA have any inventory of a Product
for which Regulatory Approval has been obtained prior to termination, MAGENTA shall have [***] thereafter in which to dispose of such inventory (subject to the payment to HDPR of any royalties due hereunder arising from such disposition); 

(c) each Party shall reasonably promptly return or, at the written election of the Disclosing Party, destroy all Confidential Information of
the Disclosing Party in its possession or control that are solely related to the terminated Product, Non-Exclusive Research Target, Exclusive Research Target or Development Target; provided that
each Party may keep one archival copy of such Confidential Information; and 
 (d) neither Party shall be relieved of any obligation that
accrued prior to the effective date of such termination. 

  
 36 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 18.3.2 Termination in its Entirety. Upon any termination of this Agreement in its
entirety by HDPR for MAGENTA’s insolvency in accordance with Section 18.2.2 or by MAGENTA for HDPR’s insolvency in accordance with Section 18.2.2 or
at-will pursuant to Section 18.2.3: 
 (a) all rights and licenses granted
by a Party to another Party under this Agreement; provided that MAGENTA’s grant of the Grant-Back License to HDPR shall not terminate; 

(b) should MAGENTA have any inventory of any Product approved and allocated prior to termination for sale in the Territory, MAGENTA shall have
[***] thereafter in which to dispose of such inventory (subject to the payment to HDPR of any royalties due hereunder arising from such disposition); 

(c) each Party shall reasonably promptly return or, at the written election of the Disclosing Party, destroy all Confidential Information of
the Disclosing Party in its possession or control; provided that each Party may keep one archival copy of such Confidential Information; and 

(d) neither Party shall be relieved of any obligation that accrued prior to the effective date of such termination. 

18.3.3 Effects of Expiration. Upon any expiration of this Agreement with respect to a given country and a given Product, or in its
entirety: 
 (a) the licenses with respect to the HDPR IP Rights and HDPR IP Improvements granted to MAGENTA under
Section 3 with respect to such country and such Product shall be conclusively deemed to continue to remain in full force and effect and shall be fully paid-up, perpetual and
irrevocable; 
 (b) all amounts due or payable to HDPR that were accrued, or that arise out of acts or events occurring, prior to the
effective date of expiration shall remain due and payable, but no additional amounts shall be payable based on events occurring after the effective date of termination; 

(c) HDPR shall reasonably promptly return or, at the written election of MAGENTA, destroy all Confidential Information of MAGENTA in its
possession or control; provided that HDPR may keep one archival copy of such Confidential Information; and 
 (d) neither Party
shall be relieved of any obligation that accrued prior to the effective date of such termination. 
 18.3.4 Rights in Lieu of
Termination. In the event that MAGENTA has the right to terminate this Agreement pursuant to Section 18.2.1 with respect to a Product, Non-Exclusive Research Target, Exclusive
Research Target or Development Target on account of HDPR’s gross negligence or willful misconduct, then, without prejudice to any other rights or remedies MAGENTA may have at law or in equity, MAGENTA may elect, in lieu of such termination, to
not terminate this Agreement but have all future payments payable to HDPR with respect to such Product, Non-Exclusive Research Target, Exclusive Research Target or Development Target, after the application of
all available reductions and deductions to such payments hereunder, shall be reduced so that the payments MAGENTA owes HDPR under this Agreement are the greater of (a) [***] or (b) [***]. 

  
 37 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 18.4 Rights in Bankruptcy. 

18.4.1 Applicability of 11 U.S.C. § 365(n). All rights and licenses (collectively, the “Intellectual Property”)
granted under or pursuant to this Agreement, including all rights and licenses to use Improvements or enhancements developed during the Agreement Term, are intended to be, and will otherwise be deemed to be, for purposes of Section 365(n) of
the United States Bankruptcy Code (the “Bankruptcy Code”) or any analogous provisions in any other country or jurisdiction, licenses of rights to “intellectual property” as defined under Section 101(35A)of the
Bankruptcy Code. The Parties agree that the licensee of such Intellectual Property under this Agreement will retain and may fully exercise all of its rights and elections under the Bankruptcy Code, including Section 365(n) of the Bankruptcy
Code, or any analogous provisions in any other country or jurisdiction. All of the rights granted to either Party under this Agreement will be deemed to exist immediately before the occurrence of any Insolvency Event in which the other Party is the
debtor. 
 18.4.2 Rights of Non-Debtor Party in Bankruptcy. If an Insolvency Event is
commenced by or against either Party under the Bankruptcy Code or any analogous provisions in any other country or jurisdiction, the non-debtor Party will be entitled to a complete duplicate of (or complete
access to, as appropriate) any Intellectual Property and all embodiments of such Intellectual Property, which, if not already in the non-debtor Party’s possession, will be delivered to the non-debtor Party within [***] of such request; provided that the debtor Party is excused from its obligation to deliver the Intellectual Property to the extent the debtor Party continues to perform all
of its obligations under this Agreement and the Agreement has not been rejected pursuant to the Bankruptcy Code or any analogous provision in any other country or jurisdiction. 

18.5 Survival. In addition to any section, article of provision that is expressly stated to survive termination or expiration of this
Agreement, Article 1 (Definitions); Section 3.6 (Grant-Back License); Section 3.7 (with respect to surviving sublicenses); Section 6.1.3 (Further Assurances);
Section 7.2 (Right of Reference); Article 12 (Auditing); Section 13.1 (Background IP); Section 13.2 (Ownership of Inventions);
Section 13.3 (German Statute on Employee’s Inventions); Section 13.4 (Trademarks); Article 15 (Indemnification); Article 16 (Limitation of Liability; Disclaimer); Article 17
(Obligation Not to Disclose Confidential Information); Section 18.3 (Consequences of Termination) and Article 19 (Miscellaneous) shall survive any expiration or termination of this Agreement for any reason. 

19. Miscellaneous. 
 19.1 Governing Law;
Place of Jurisdiction. This Agreement shall be governed by the laws of the State of New York, USA, without regard to any conflicts of laws concepts that would apply the substantive law of some other jurisdiction. Any disputes arising out of this
Agreement or any other stipulations in connection with this Agreement are to be decided by the competent court of law. Place of jurisdiction for both Parties is New York, NY, US, and each Party irrevocably submits to the exclusive jurisdiction of
and laying of venue in such courts. Notwithstanding the foregoing, each Party shall have the right to seek injunctive or other equitable relief from any court of competent jurisdiction as may be necessary to avoid irreparable harm, without the need
to post any security. 
 19.2 Disputes. Unless otherwise set forth in this Agreement, in the event of any dispute in connection with
this Agreement, such dispute shall be referred to the respective executive officers of the Parties designated below or their designees, for good faith negotiations attempting to resolve the dispute. If the executive officers (or their designees) are
unable to resolve such dispute within [***] of such dispute first being referred to them for resolution, then either Party may avail itself to any other remedies it has at law or in equity, subject to Sections 19.1. The designated executive
officers are as follows: 
  

			
	             For HDPR:
	  	 CEO

	             For MAGENTA:
	  	 CEO

  
 38 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 19.3 Assignment. Neither Party may assign this Agreement without the prior written
consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed, except that such consent shall not be required in connection with any assignment to (a) an Affiliate of the assigning Party or (b) a
Third Party in connection with a sale or transfer of the business to which this Agreement relates or to any successor Person resulting from any merger or consolidation of such Party with or into such Person; provided that, with respect
to each ((a)-(b)), the assignee shall have agreed in writing to assume all of the assignor’s obligations hereunder; and provided, further, that the other Party shall be notified promptly after such assignment has been
effected. In the event of a Change of Control of HDPR (other than through an internal restructuring of the companies comprising the dievini Group), HDPR or its successor shall perform a Non-GMP Partial
Manufacturing Technology Transfer, a Non-GMP Full Manufacturing Technology Transfer or a GMP Full Manufacturing Technology Transfer, as requested by MAGENTA in writing, for the benefit of MAGENTA against
payment of fees as set forth in this Agreement. 
 19.4 Independent Contractor. No employee or representative of either Party shall
have any authority to bind or obligate the other Party to this Agreement for any sum or in any manner whatsoever or to create or impose any contractual or other liability on the other Party without said Party’s prior written approval. For all
purposes, and notwithstanding any other provision of this Agreement to the contrary, each Party’s legal relationship to the other Party under this Agreement shall be that of independent contractor. 

19.5 Unenforceable Provisions and Severability. If any of the provisions of this Agreement are held to be void or unenforceable, then
such void or unenforceable provisions shall be replaced by valid and enforceable provisions that will achieve, as far as possible, the economic business intentions of the Parties. However, the remainder of this Agreement will remain in full force
and effect; provided that the material interests of the Parties are not affected (i.e., the Parties would presumably have concluded this Agreement without the unenforceable provisions). 

19.6 Waiver. The failure by either Party to require strict performance or observance of any obligation, term, provision or condition
under this Agreement will neither constitute a waiver thereof nor affect in any way the right of the respective Party to require such performance and/or observance. The waiver by either Party of a breach of any obligation, term, provision or
condition hereunder shall not constitute a waiver of any subsequent breach thereof or of any other obligation, term, provision or condition. No waiver of any obligation under or provision of this Agreement shall be valid or effective unless in
writing and signed by each of the Parties. 
 19.7 Appendices. All Appendices to this Agreement shall form an integral part to this
Agreement. 
 19.8 Amendments. No amendments of the terms and conditions of this Agreement shall be binding upon either Party hereto
unless in writing and signed by both Parties. 

  
 39 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 19.9 Further Assurances. Each Party agrees to do and perform all such further acts and
things and shall execute and deliver such other agreements, certificates, instruments and documents necessary or that the other Party may deem advisable in order to carry out the intent and accomplish the purposes of this Agreement and to evidence,
perfect or otherwise confirm its rights hereunder. 
 19.10 Invoice Address. All invoices that are required or permitted hereunder
shall be in writing and sent by HDPR to MAGENTA at the following address: 
 50 Hampshire St. – 8th floor 
 Cambridge, MA 02139 USA 

19.11 Notice. All notices that are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by
facsimile or electronic mail (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt
requested, addressed as follows: 
  

			
	 if to HDPR, to:
	  	 Heidelberg Pharma Research GmbH

[***]

Schreisheimer Strasse 101

68526 Ladenburg

Germany

[***]

		
	 And:
	  	 [***]

		
	 if to MAGENTA, to:
	  	 Magenta Therapeutics, Inc.

50 Hampshire St. 8th floor

Cambridge, MA 02139 USA

[***]

		
	 And:
	  	 [***]

 or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in
accordance herewith. Any such notice shall be deemed delivered on the date received. 
 19.12 Rules of Construction. Headings and
captions are for convenience only and are not be used in the interpretation of this Agreement. Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, any
rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. In construing this Agreement (a) use of the singular includes the plural and vice versa; (b) “include” or
“including” shall mean without limitation by reason of enumeration, (c) the words “herein”, “hereof, “hereunder” and other words of similar import refer to this Agreement as a whole and not to any particular
provision, (d) except where the context otherwise requires, the word “or” is used in the inclusive sense; and (e) the words “shall” and “will” will be construed as equivalents and neither word shall be deemed
to be more permissive than the other. Accounting terms not otherwise defined herein have the meanings given to them in accordance with the applicable Accounting Standard. 

19.13 Counterparts. This Agreement may be executed in counter-parts with the same effect as if both Parties had signed the same
document. All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument. Signatures to this Agreement transmitted by email in “portable document format” (“.pdf), or by
any other electronic means intended to preserve the original graphic and pictorial appearance of this Agreement shall have the same effect as physical delivery of the paper document bearing original signature. 

[Signature pages follow.] 

  
 40 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 IN WITNESS WHEREOF, the Parties, acting through their duly authorized representatives,
have entered into this Agreement as of the Effective Date. 
  

									
	Heidelberg Pharma Research GmbH	 		  		 	
					
	By:	 	 /s/ Jan Schmidt-Brand
	 		  	By:	 	 /s/ Marcel Linssen

	Name:	 	 Dr. Jan Schmidt-Brand
	 	        	  	Name:	 	 Marcel Linssen

	Title:	 	 Chief Executive Officer
	 		  	Title:	 	 Chief Business Officer

				
	Magenta Therapeutics, Inc.	 		  		 	
					
	By:	 	 /s/ Jason Gardner
	 		  	By:	 	 /s/ Christina Isacson

	Name:	 	 Jason Gardner
	 		  	Name:	 	 Christina Isacson

	Title:	 	 CEO
	 		  	Title:	 	 CBO

 [Signature Page to Exclusive Research, Development Option and License Agreement] 

  
 41 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 Appendix 1 

RESEARCH PLAN 
 MAGENTA is currently
developing four ADC profiles to address patient conditioning unmet needs in hematopoietic stem cell transplantation (HSCT). Lead antibodies to [***], have been evaluated. MAGENTA continues to evaluate tool antibodies to [***] and will launch
antibody discovery campaigns to discover lead antibodies against these targets in early 2018. Through this Research Plan (“Plan”) MAGENTA will continue to progress [***]. 

As part of this Plan HDPR will work with MAGENTA to provide [***]. 

Both MAGENTA and HDPR will discuss each parties’ role in performing conjugations. Both parties will agree to a certain number of conjugation slots per
quarter to be performed on behalf of MAGENTA at HDPR. 
 Target 1 

MAGENTA plans to [***]. Through ongoing MTA agreements with HDPR, MAGENTA has made considerable progress in [***]. [***]. 

Estimated timelines and sequence of steps for Target 1 research plan are in the attached appendix and include the steps described below: 

Step 1: Evaluation of alternate amanitin linker payloads ([***]) 

To allow full evaluation of HDPR’s amanitin technology MAGENTA would like access to research quantities [***]. 

The following steps assume [***]. MAGENTA and HDPR to discuss potential of evaluating other linker payloads in parallel after Step 1 Evaluation phase.

 Step 2: Developability Assessment ([***]) 

MAGENTA will require [***]. [***]. [***]. 
 Rationale:

 It is expected that [***]. All antibodies will be subjected to conjugation optimization followed by selecting conditions for scale up. ADCs will be
characterized using above mentioned assays for binding, in-vitro/in-vivo studies, early formulation, developability and accelerated stability studies. It is expected
that batch sizes will vary between [***] depending upon the scope of studies. 
 Step 3: Perform Demo Batches ([***]) 

To gain experience and inform selection of a CMO for GMP conjugation MAGENTA plans to perform demo batches at [***]. Each CMO will [***]. 

  
 42 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 Rationale: 
 A
reference standard will be prepared at MAGENTA which is expected to consume [***]. The reference standard will be used to generate analytical data that will serve as a standard for analytical results from CMOs. Each CMO will perform conjugation
optimization which is expected to consume [***]. ADCs prepared at CMOs will be tested at MAGENTA for characterization and analysis. 
 The final decision
for linker/payload is [***]. Change of linker will [***]. 
 Step 4: Prepare [***] 

MAGENTA plans to execute [***] to gain further understanding of the activity, toxicity and pharmacokinetic profile of our lead ADC. [***]. Conjugations
performed at HDPR or MAGENTA at [***]. [***]. 
 Step 5: Formulation and Process Development ([***]) 

MAGENTA requires [***]. [***]. Conjugation parameters [***] such as [***] will also be optimized. The optimized process will be expected to maintain
[***]. A panel of formulations will also be developed to assess ADC stability. [***]. Buffers will be made with [***]. 
 Step 6: Analytical Method
Development ([***]) 
 MAGENTA requires [***]. MAGENTA’s analytical group has developed [***]. [***]. 

As Part of method development, MAGENTA will require [***]. 

Step 7: Process and Formulation Development at CMO ([***]) 

MAGENTA requires approximately [***]. Activities include [***]. 

Step 8: Tech transfer, method qualification / validation and release assays at CMOs ([***]) 

MAGENTA requires approximately [***]. Activities include [***]. 

Step 9: Engineering/GLP Tox Manufacturing ([***]) 

[***]. 
 Step 10: GMP Manufacturing ([***])

 [***]. 
 Target 1 Timeline 

[***] 

  
 43 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 Target 2 [***] 

Step 1: Evaluation/Discovery Phase 
 MAGENTA is
developing a second ADC against Target 2. Currently MAGENTA is [***]. 
 Steps 2-10: Development Phase

 Once a lead is identified for Target 2 ADC ([***]. 

Targets 3 and 4 [***] 
 Step 1: Evaluation/Discovery
Phase 
 MAGENTA is [***]. 
 Steps 2-10: Development Phase 
 [***]. 

  
 44 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 Appendix 2 

Service Cost List 
 [To be
added after the Effective Date.] 

  
 45 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 Appendix 3 

Press Release* 
 (see
Note to the Agreement at the end of the Press Release) 
 Magenta Therapeutics and Heidelberg Pharma Sign Exclusive Multi-Target Research Agreement
for the Development of Antibody Drug Conjugates 
  

	 	•	 	Collaboration enables and accelerates Magenta’s research and development efforts across several targeted conditioning programs for bone marrow transplant 

 

	 	•	 	Expands application of Heidelberg Pharma ATAC technology to new targets 

 Ladenburg, Germany, and Cambridge,
MA, USA, xx February 2018—Heidelberg Pharma AG (FSE:WL6), a biotechnology company developing new options to address major challenges in cancer therapy, and Magenta Therapeutics Inc., a biotechnology company developing therapeutics to
improve and extend the use of curative bone marrow transplant for more patients, today announced the signing of an exclusive multi-target research agreement. Heidelberg Pharma Research GmbH signed this collaboration, which will combine
Magenta’s stem cell platform with proprietary antibodies across up to four exclusive targets with Heidelberg Pharma’s proprietary ATAC (Antibody Targeted Amanitin Conjugates) platform. 

“There is a significant need for targeted conditioning regimens for bone marrow transplant, and this is a key area of focus for Magenta. Our partnership
with Heidelberg Pharma is an important step in our development of proprietary targeted antibody drug conjugates for conditioning,” said Michael Cooke, Ph.D., Chief Scientific Officer, Magenta Therapeutics. “Amanitin is one of the promising
toxins we are exploring in our targeted conditioning programs, and our partnership with Heidelberg Pharma will allow us to fully evaluate the potential of this payload.” 

“We are delighted to collaborate with Magenta Therapeutics, a company at the forefront of transforming the field of bone marrow transplant medicine. We
believe this partnership further validates our technology and underscores our leadership in the field of Antibody Targeted Amanitin Conjugates, a new mode of action for attacking cancer,” said Andreas Pahl, Ph.D., Chief Scientific Officer,
Heidelberg Pharma. “We look forward to working with Magenta to expand the application of our ATAC technology to new targets to potentially address unmet needs in bone marrow transplantation.” 

Under the terms of the multi-target research agreement, Magenta will have access to Heidelberg Pharma’s Amanitin toxin-linker platform technology.
Magenta has an option for an exclusive target-specific license for global development and commercialization rights to each of the product candidates resulting from the research collaboration. 

Heidelberg Pharma will receive upfront technology access and exclusivity fees and payments for research support. Under the exclusive license agreement,
Heidelberg Pharma would be eligible to receive option fees, clinical development, regulatory and sales-related milestone payments up to $334 million USD, if Magenta exercises all target options and all milestones are met. 

  
 46 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 About Bone Marrow Transplant 

Healthy bone marrow stem cells and the blood cells they create are crucial for survival, but certain diseases can affect the bone marrow, interfering with its
ability to function properly. A bone marrow transplant is a process to replace unhealthy bone marrow with healthy bone marrow stem cells. Bone marrow transplant can save the lives of patients with blood cancers and genetic diseases and is a
potential cure for patients with severe refractory autoimmune diseases. However, the high risks, toxic side effects and complexity of the procedure currently prevent many patients from being able to benefit. 

About Heidelberg Pharma 
 Heidelberg Pharma is an oncology
specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic
principle. This proprietary technology platform is being applied to develop the Company’s proprietary therapeutic ATACs as well as in third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma. ATAC technology is the core activity of subsidiary Heidelberg Pharma Research GmbH. 

Heidelberg Pharma AG has entered into partnerships to further develop and commercialize its clinical assets MESUPRON® and REDECTANE®, while RENCAREX® is available for
out-licensing and further development. The Company is listed on the Frankfurt Stock Exchange: ISIN DE000A11QW0 / WKN A11QW / Symbol WL6. More information is available at www.heidelberg-pharma.com. 

About Magenta Therapeutics 
 Magenta Therapeutics is a
biotechnology company developing therapeutics to revolutionize bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of transplant medicine, Magenta
Therapeutics is pioneering an integrated approach to extend the curative power of bone marrow transplant to more patients. Founded by internationally recognized leaders in bone marrow transplant medicine, Magenta Therapeutics was launched in 2016 by
Third Rock Ventures and Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit www.magentatx.com. 
  

			
	 Heidelberg Pharma AG
 Sylvia
Wimmer
Tel.: +49 89 41 31 38-29
Email: investors[at]hdpharma.com
  

Business Development
Dr. Marcel Linssen
CBO, Executive Vice President
Tel.: +49 6203 1009-40
Email:
m.linssen[at]hdpharma.com
	  	IR/PR support
MC Services AG
Katja Arnold (CIRO)
Managing Director & Partner
Tel.: +49 89-210 228-40
Email: katja.arnold[at]mc-services.eu
		
	Magenta Therapeutics:
Manisha Pai,
Vice President, Communications &
Investor
Relations
857-242-1155
mpai@magentatx.com	  	

  
 47 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 This communication contains certain forward-looking statements relating to the Company’s business, which
can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar
expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial
condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors
and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments. 

*Note to the Agreement: The order in which the Parties are mentioned the course of the press release may vary according to the Party issuing the press
release. 

  
 48 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 Schedule 1.31 

Initial Targets 
 [***] 

  
 49 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 Schedule 1.36 

Patent Rights 
 [***] 

  
 50 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 Schedule 6.1.1(c)(ii) 

Know-How for Non-GMP Partial Manufacturing Technology
Transfer 
 [***] 

  
 51 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 Schedule 6.1.2(b) 

Know-How for Non-GMP Full Manufacturing Technology Transfer

 [***] 

  
 52 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 Schedule 6.2.1(c) 

Know-How for GMP Full Manufacturing Technology Transfer 

[***] 

  
 53 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 Schedule 6.1.4 

Pre-Clinical Supply Terms and Conditions 

(a) General. In connection with HDPR’s or its Third Party designee’s supply of Antibody-drug conjugate material, Amanitin
Toxin Constructs or Amanitin to MAGENTA pursuant to Section 6.1.1, HDPR shall or shall cause its Third Party designee to manufacture and supply such Antibody-drug conjugate material, Amanitin Toxin Constructs and Amanitin
pursuant to the terms of this Agreement and the written specifications provided to HDPR from time to time. The JSC shall periodically review the specifications and make any necessary changes, including any changes required by Regulatory Authorities
in countries where Regulatory Approval for the Antibody-drug conjugate material, Amanitin Toxin Construct or Amanitin has been approved or is pending. 

(b) Orders; Delivery; Storage. MAGENTA will order Antibody-drug conjugate material, Amanitin Toxin Constructs and Amanitin from HDPR in
accordance with the terms of Section 6.1.1(c)(i). HDPR shall deliver Antibody-drug conjugate material, Amanitin Toxin Constructs and Amanitin in accordance with the terms of Section 6.1.1(c)(i).
Orders may be amended only by mutual agreement of the Parties. HDPR shall store the Antibody-drug conjugate material, Amanitin Toxin Constructs or Amanitin in accordance with the specifications, any quality agreements entered into by the Parties and
Applicable Law. 
 (c) Rejection. MAGENTA may reject any Antibody-drug conjugate material, Amanitin Toxin Construct or Amanitin that
does not conform to the specifications, any quality agreements entered into by the Parties or Applicable Laws by providing written notice of such rejection to HDPR within [***]hereof; provided, however, that there shall be no time
restrictions applicable to MAGENTA’s provision of a notice of rejection of any shipments of Antibody-drug conjugate material, Amanitin Toxin Construct or Amanitin (or portion thereof) where any of the following have occurred or are present:
(1) latent defects that are not reasonably discoverable by MAGENTA through standard inspection and testing; or (2) breach by HDPR of any of its representations or warranties set forth in subsection (e) hereof. MAGENTA shall promptly
return any rejected Antibody-drug conjugate material, Amanitin Toxin Construct or Amanitin to HDPR at HDPR’s expense and may elect, in its sole discretion, upon written notice to HDPR: (I) to have HDPR replace the rejected Antibody-drug
conjugate material, Amanitin Toxin Construct or Amanitin as soon as practicable at no additional charge to MAGENTA (and in no case later than [***]); or (II) to not have HDPR replace the rejected Antibody-drug conjugate material,
Amanitin Toxin Construct or Amanitin (or portions thereof) and, instead, have HDPR promptly reimburse MAGENTA (and in no case later than [***]) for any amounts that MAGENTA has already paid to HDPR for such rejected Antibody-drug conjugate material,
Amanitin Toxin Construct or Amanitin (or portions thereof). If the Parties are unable to agree on whether any Antibody-drug conjugate material, Amanitin Toxin Construct or Amanitin was properly rejected by MAGENTA pursuant to this subsection (c),
then such dispute will be resolved in accordance with Section 19.2. 
 (d) Destruction of Rejected
Materials. Any Antibody-drug conjugate material, Amanitin Toxin Construct or Amanitin rejected by MAGENTA pursuant to subsection (c) shall be disposed of by HDPR in a manner that prevents theft and diversion and in accordance with
Applicable Laws. 

  
 54 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 (e) Manufacturing Representations and Warranties. All Antibody-drug conjugate
material, Amanitin Toxin Construct or Amanitin manufactured and supplied by HDPR or its designee under this Agreement shall: 
  

	 	(i)	be manufactured, packaged, labeled, handled, stored and shipped in accordance with, shall be of the quality specified in, and shall conform to, this Agreement, the specifications, Applicable Laws and any quality
agreements entered into by the Parties; 

  

	 	(ii)	not contain any material that has not been used, handled or stored in accordance with this Agreement, the specifications, Applicable Laws and any quality agreements entered into by the Parties; 

 

	 	(iii)	not be adulterated or misbranded within the meaning of Sections 501 and 502, respectively, of the FDCA and any other Laws; 

  

	 	(iv)	be free from defects in material and workmanship; and 

  

	 	(v)	at the time delivered, have a remaining shelf-life as specified in the applicable specifications set forth by the JSC. 

  
 55

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}]]